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Seventh International Conference on Novel Psychoactive Substances 
 
In recent years, there has been a dramatic increase in the number of new psychoactive substances (NPS) detected across 
the world. The NPS market remains highly dynamic and is characterised by the emergence of large numbers of new 
substances reported in a growing number of countries. Between 2009 and 2018, 119 countries and territories reported the 
emergence of 950 NPS to the United Nations Office on Drugs and Crime (UNODC), through the UNODC Early Warning 
Advisory on NPS. In Europe, since 1997, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 
has been monitoring and responding to NPS appearing in the EU through the EU Early Warning System on NPS. At the 
end of 2019, the EMCDDA was monitoring around 790 NPS, 90% of which were identified for the first time in the last 
decade. The increase in the number and availability of NPS in recent years has largely been driven by globalisation, the 
internet and rapid changes in technology. Yet, recently, there have been some encouraging signs. For example, the number 
of NPS reported annually for the first time in Europe has dropped from a high of around 100 in 2014 and 2015 to around 
50 in 2017, 2018 and 2019. Nevertheless, NPS continue to pose numerous challenges in terms of detecting and 
monitoring; understanding patterns of use and harms caused; and developing appropriate public health responses. In 
Europe, around one new substance is still detected every week, increasing the overall number that needs to be monitored. 
Major new problems have also emerged, that have led to an increasing number and range of risks for people who use 
psychoactive substances. These include an increase in the number of highly potent NPS on the market — many of which 
are synthetic cannabinoids or synthetic opioids — and the COVID-19 pandemic. Given the numerous challenges posed 
by NPS, we are pleased to launch the International Society for the Study of Emerging Drugs (ISSED) to strengthen 
multidisciplinary and international collaboration to enhance knowledge and improve the quality of information-sharing 
in this complex area in a more coordinated way. In this context, the NPS conference series, now in its 7th edition, is the 
major international forum on NPS, attracting hundreds of participants worldwide. This year’s conference is jointly 
organised by the ISSED, UNODC, the EMCDDA, the World Anti-Doping Agency (WADA), the University of 
Hertfordshire (UH) and the Centre for Forensic Science Research & Education (CFSRE). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONFERENCE ABSTRACTS 
 
(in alphabetical order) 
 
Image Enhancing Drugs: an overlooked phenomenon? 
Al-Sarraf A. *, Bewley A., Corazza O. 
* Department of Clinical Pharmaceutical and Biological Sciences, School of Life and Medical Sciences University of 
Hertfordshire, United Kingdom - a.al-sarraf@herts.ac.uk 
 
Background: In a society that strives for beauty and perfection, people are increasingly adopting risky behaviours to 
enhance their body image. One of these behaviours is the use of skin-lightening products. Those products are available 
to buy from unregulated internet websites with no medical prescriptions. Some of these products might contain 
contaminants, or undisclosed ingredients, which are responsible for skin or systemic side-effects. On the other hand, little 
is known about the motivational factors behind this risky practice including the presence of psychological problems such 
as Body Dysmorphic Disorder (BDD) among others. Methods: Mixed qualitative and quantitative approaches have been 
used in clinical and non-clinical settings. After an initial literature review, an internet-based research has been carried out 
in beauty and skin care websites. Also, a semi-structured questionnaire has been administered online and in dermatology 
clinics. In addition, participants who are interested have been invited to attend a face-to-face in-depth semi-structured 
interview with the researcher. Results: Results of the thematic analysis of both online forums data and face to face 
interviews have yielded three prominent motivational themes behind the practice of skin lightening which are 1) 
Sociocultural related factors including getting influenced from other people or online resources, 2) Skin related conditions 
especially hyperpigmented lesions, and 3) Psychological related factors including body image concerns. Also, it has been 
revealed that skin lightening agents are divided into topical which are easily found agents online or in stores and systemic 
ones e.g. intravenous treatments which are available from online resources and some clinics. Conclusions: Many skin 
side-effects have been reported with skin lightening products use such as thinning of skin, visible veins, stretch marks, 
irritation, peeling, patchy discoloration, acne, pimples, etc. Moreover, skin lightening can be accompanied by bullying 
experience and other psychological impacts. Results of the quantitative data are in progress and will be revealed at the 
day of conference. 
 
International Snapshot of Novel Psychoactive Substance Use: Case study of ten countries over the 2019/2020 New 
Year Period 
Bade R.*, White J.M., Barron L., Baz-Lomba J.A., Been F., Bijlsma L., Burgard D.A., Castiglioni S., Celma A., Chappell 
A., Covaci A., Emke E., Hernandez F., Salgueiro-Gonzalez N., van Nuijs A.L.N., Wang D., Zuccato E., Gerber C. 
* Health and Biomedical Innovation, UniSA: Clinical and Health Sciences, University of South Australia, Australia – 
richard.bade@unisa.edu.au 
 
Background: Despite the best efforts of government legislation, novel psychoactive substances (NPS) are continually 
evolving, with almost 1000 NPS having been reported to the UNODC. With little to no information available on “safe” 
doses, side effects and toxicity, it is important to monitor community consumption of these substances, particularly over 
festive periods. Wastewater analysis has proven itself invaluable in this regard, due to its ability to anonymously monitor 
consumption within a community through the wastewater. An international study was thus carried out by sampling 
simultaneously in ten countries over the 2019/20 New Year period to investigate which NPS are most prevalent and 
whether any geographic patterns are evident. Methods: Influent wastewater samples were collected from up to four sites 
per country in ten countries (Australia, United States, New Zealand, Italy, Spain, Norway, China, Belgium, the 
Netherlands and the United Kingdom) from December 26, 2019 – January 3, 2020. Samples were loaded onto solid phase 
extraction cartridges in the countries of origin before being shipped to the University of South Australia for elution and 
sample analysis. All samples were analysed with two liquid chromatography - mass spectrometry methods. One employed 
a (semi)quantitative targeted method for 21 NPS and the other a qualitative high-resolution mass spectrometry screening 
method with a database of more than 200 NPS. Results: A total of nine NPS were semi-quantified in the samples: 4-
fluoroamphetamine, 4-methylethcathinone, mephedrone, 3-methylmethcathinone, N-ethylpentylone, methcathinone, 
ethylone, pentylone and methylone. A further seven were qualitatively found: 4-fluoromethamphetamine, 4-
chloromethcathinone, mitragynine, ketamine, norketamine, acetyl fentanyl and eutylone. In samples from Norway and 
China, only ketamine and its metabolite norketamine were seen.  N-ethylpentylone was the most prevalent NPS being 
found in New Zealand, Australia and the United States. Mephedrone had the highest mass load of all NPS. It is interesting 
to note the geographic specificities of some of the substances – 3-methylmethcathinone was only seen in Spain, the 
Netherlands and Italy; mephedrone and eutylone in New Zealand, United States, the Netherlands and Australia; 4-
chloromethcathinone in Italy, 4-fluoroamphetaminbe, 4-methylethcathinone and 4-fluoromethamphetamine in the 
Netherlands and mitragynine and acetyl fentanyl in the United States. Conclusions: This work has shown the utility of 
wastewater analysis to monitor community consumption of NPS. A snapshot into the consumption of NPS consumption 
in ten countries was made by analysing samples over the 2019-20 New Year period. A total of 16 substances were found, 
with synthetic cathinones the most common.  
 
Analytical, pharmacological, and toxicological evaluation of prevalent synthetic cannabinoid receptor agonists 
Banister S.  
The University of Sydney, Australia - samuel.banister@sydney.edu.au  
 
Background: More than 250 synthetic cannabinoid receptor agonists (SCRAs) have been identified in recreational drug 
markets across the globe since the first examples were detected a decade ago. SCRAs are increasingly associated with 
mass intoxications involving severe illness and death. Methods: We have used a modular, divergent synthetic approach 
to rapidly and proactively develop a library of recent SCRAs and metabolites based on structural trends in the SCRA 
marketplace. The SCRA library was screened at human cannabinoid type 1 and type 2 receptors (CB1 and CB2, 
respectively) using radioligand binding assays and fluorescence-based plate reader membrane potential assays, and 
evaluated in mice using radiobiotelemetry. Through the Psychoactive Surveillance Consortium and Analysis Network 
(PSCAN), we have used liquid chromatography−quadrupole time-of-flight−mass spectrometry (LC-QTOF-MS to screen 
for all members of the library in patient samples from multiple partner sites in the US. Results: Many of the most recently 
detected SCRAs, such as CUMYL-CBMICA, ADB-BUTINACA, 4F-MDMB-BINACA, AMB-4en-PINACA, and 5F-
AB-P7AICA, showed nanomolar affinity for CB1 and CB2 receptors. Unlike Δ9-THC, most recent SCRAs were found 
to act as high efficacy agonists of CB1 and CB2, with greater potency than Δ9-THC itself. Moreover, many of these 
compounds demonstrated potent cannabimimetic activity in mice, inducing central CB1-mediated hypothermia, 
hypolocomotion, and bradycardia with greater potency than Δ9-THC. Several SCRAs showed potent proconvulsant 
activity in mice, consistent with reports of seizure in human users of these substances. PSCAN has detected many SCRAs 
from this library in patient blood samples, including derivatives not yet reported by forensic chemistry groups, 
underscoring the value of a proactive approach to the synthesis and characterization of emerging SCRAs and their 
analogues, and the clinical confirmation of SCRAs in toxicology cases. Conclusions: Structure-activity relationships for 
the CB1 and CB2 receptor binding and agonist activity of the most recent and prevalent SCRAs, including CUMYL-
CBMICA, ADB-BUTINACA, 4F-MDMB-BINACA, AMB-4en-PINACA, 5F-AB-P7AICA and their analogues have 
been identified. Key structural features contributing to CB1 agonist potency in vitro and in vivo were determined. Several 
SCRAs identified in illicit drug markets were observed to cause seizures in mice, consistent with clinically noted adverse 
effects in humans. The proactive generation of SCRA analogue libraries, and the utility of such libraries to the rapid 
detection of emerging drugs of abuse by clinical toxicologists, was demonstrated. The unprecedented potency and efficacy 
of many recently identified SCRAs at CB1 receptors may contribute to the clinical toxicity of these substances.  
  
Designer Benzodiazepines: What's In Fake "Xanax"? 
Blakey K.*, Thompson A., Griffiths A. 
* Queensland Health Forensic and Scientific Services, Queensland, Australia - Karen.Blakey@health.qld.gov.au 
 
Not available 
 
Identification of isotonitazene, the first member of a novel emerging class of legal, highly potent benzimidazole NPS 
opioids 
Blanckaert P. 
Belgian Early Warning System Drugs, OD Epidemiology, Sciensano, Brussels, Belgium – peter.blanckaert@sciensano.be 
 
Background: We report on the identification and full chemical characterization of isotonitazene (N,N-diethyl-2-[5-nitro-
2-({4-[(propan-2-yl)oxy]phenyl}methyl)-1H-ben-zimidazol-1-yl]ethan-1-amine), the first member of a new class of 
(ultra)potent benzimidazole opioids, legally available on online markets. Methods and Results: Identification of 
isotonitazene was performed by gas chromatography mass spectrometry (GC–MS) and liquid chromatography time-of-
flight mass spectrometry (LC-QTOF-MS), the latter identifying an exact-mass m/z value of 411.2398. All 
chromatographic data indicated the presence of a single, highly pure compound. Confirmation of the specific 
benzimidazole regio-isomer was performed using 1H and 13C NMR spectroscopy, after which the chemical 
characterization was finalized by recording Fourier-transform (FT-IR) spectra. A live cell-based reporter assay to assess 
the in vitro bio-logical activity at the μ-opioid receptor (MOR) revealed that isotonitazene has a high potency (EC50 of 
11.1 nM) and efficacy (Emax 180% of that of hydromorphone), thus confirming that this substance is a very potent opioid. 
Conclusions: Isotonitazene has not been previously detected, either in powder form, or in biological fluids. The high 
potency and efficacy of isotonitazene, combined with the fact that this compound was being sold undiluted, represents an 
imminent danger to anyone ordering legal opioids online. 
 
Ambient ionization mass spectrometry applied to new psychoactive substance analysis 
Boronat M.*, Cowan D., Abbate V.  
* King’s College, London, United Kingdom 
 
Background: In the past decade, the world has seen the emergence of new drugs that have similar effects to controlled 
psychoactive drugs, like amphetamines or lysergic acid diethylamide. These drugs can collectively be classified under 
the term new psychoactive substances (NPS) and are used for recreational purposes. The novelty of the substances, 
alongside the rate of emergence and structural variability, makes their detection as well as their legal control more 
difficult, increasing the demand for rapid and easy-to-use analytical techniques for their detection and identification. 
Therefore, interest in ambient ionization mass spectrometry (AIMS) applied to NPS has grown in recent years. This is 
largely because of the relatively fast, simple and low operating cost of AIMS, allowing the ionization of the analyte(s) of 
interest at atmospheric pressure from unprepared samples. This review aims to provide an updated overview of the current 
ambient ionization techniques’ suitability for the analysis of NPS in the forensic and clinical toxicology field. Methods: 
In order to do so, peer- reviewed primary studies of the last 10 years in various databases were examined and a thorough 
appraisal of the findings was carried out. Results: The applicability of AIMS techniques to NPS analysis was found to be 
mainly compromised by ionization inefficiency, strong ion suppression, poor selectivity, low reproducibility and the 
inability to distinguish isomeric and isobaric molecules. Conclusions: With further research directed at improving the 
instrument design and at understanding the effect of sample complexity on the analyte of interest, AIMS show potential 
as an alternative technique providing minimal to no sample preparation and fast analysis time in screening applications. 
 
Emerging drugs harms: new app and tools to train clinicians  
Bowden–Jones O.  
University College London, United Kingdom - o.bowden-jones@ucl.ac.uk 
 
Not available    
 
Semi-quantitative activity-based detection of JWH-018, a synthetic cannabinoid receptor agonist, in oral fluid after 
vaping 
Cannaert A. 
Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, 
Belgium - annelies.cannaert@ugent.be  
 
Background: The rapid proliferation of new synthetic cannabinoid receptor agonists (SCRAs) has initiated considerable 
interest in the development of so-called “untargeted” screening strategies. One of these new screening technologies 
involves the activity-based detection of SCRAs. In this study, we evaluated whether (synthetic) cannabinoid activity can 
be detected in oral fluid (OF) and, if so, whether it correlates with SCRA concentrations. Methods: OF was collected at 
several time points in a placebo-controlled JWH-018 administration study. The outcome of the cell-based cannabinoid 
reporter system, which monitored the cannabinoid receptor activation, was compared to the quantitative data for JWH-
018, obtained via a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. Results: A total 
of 175 OF samples were collected and analysed via both methods. The cannabinoid reporter assay correctly classified the 
vast majority of the samples as either negative (<0.25 ng/mL; 74/75 = 99%), or having low ((0.25 – 1.5 ng/mL; 16/16 = 
100%) and 1.5 – 10 ng/mL; 37/41 = 90%)), mid (10 – 100 ng/mL; 23/25 = 92%) or high (>100 ng/mL; 16/18 = 89%) 
JWH-018 concentrations. Passing-Bablok regression analysis yielded a good linear correlation, with no proportional 
difference between both methods (slope 0.97; 95% confidence interval 0.86 – 1.14) and only a small systematic 
difference. Conclusions: This is the first study to demonstrate the applicability of an untargeted, activity-based approach 
for SCRA detection in OF (Cannaert et al. 2020 Anal Chem). Additionally, the outcome of the cannabinoid reporter assay 
was compared to the gold standard (LC-MS/MS), showing a good correlation between both methods, indicating that the 
cannabinoid reporter assay can be used for an estimation of drug concentrations.  
  
NPSfinder® designer benzodiazepines: QSAR and Docking studies 
Catalani V.*, Schifano F., Botha M., Corkery J., Guirguis A. 
* Psychopharmacology, Drug Misuse & Novel Psychoactive Substances Research Unit, School of Life & Medical 
Sciences, University of Hertfordshire, Hatfield, United Kingdom- v.catalani@herts.ac.uk 
  
Background: The non-medical use of benzodiazepines (BZDs) is considered a threat to public health. From 2017 to 2020, 
a rise in the use of designer/NPS benzodiazepines (DBZDs) was reported and evidence of health and social harms 
associated with their use/abuse published. DBZDs are strong CNS depressants and, when used in combination with other 
drugs, cause serious toxicity with profound sedation, respiratory depression, coma, and death. At date, the officially 
identified and reported (UNODC, EMCDAA) DBZDs are 31. However, a web crawling exercise over the surface web 
identified a much higher number of DBZDs, precisely 130. This finding amplifies the concern towards DBZDs with 
regards to their unknown potency, pharmacological and toxicological effects. The aim of this study was to generate QSAR 
models and conduct a molecular docking study, to investigate/predict the biological activity of these 131 DBZDs on the 
GABA-A benzodiazepine receptor. Methods: The web crawling activity was conducted with the use of an ad hoc 
software, NPSfinder®, created by the Italian IT company Damicon. QSAR and Docking studies were performed with 
MOE . To build robust training and test sets for QSAR, 78 BDZs were divided with the use of Tanimoto coefficients. 
Their experimentally derived biological activity values (log 1/C) were used to build QSAR models. 3D crystallised 
GABA-A receptor-ligand complexes from the Protein Data Bank (PDB) were used for the docking. For each of the 130 
DBZDs , an “S” value was generated that served as an indication of binding affinity. Results: The best QSAR model was 
used to predict the log 1/C values for the 130 DBZDs. Of these, 74 were found to be higher than Alprazolam (high potency 
BZD, log 1/c=7.7) suggesting a strong activity on the GABA-A. These findings were compared to the docking: some 60 
DBZDs showed a stronger binding affinity than Alprazolam. These 60 DBZDs (e.g. Cinazepam, Mp-iii-022, Ethyl 
carfuzapate, Remimazolam,etc) share some common features that can be hypothesised as important for a good binding 
affinity: an halogen or NO2 substituent on the C7 carbon of the benzodiazepine backbone, a long/bulky substituent on the 
C3, a double bond (C=O) or a five member ring substituent on C2.Conclusion: QSAR and docking studies recognised a 
large number of possibly very potent DBZDs among the ones identified on the surface web. Further studies are necessary 
to investigate/understand the relation between chemical features (pharmacophore) and biological activity and evaluate 
the threat that DBZDs may pose.  
 
Beyond the purple drank. Study of promethazine abuse according to the eudravigilance dataset 
Chiappini S.*, Schifano F., Corkery J.M., Guirguis A. 
* Psychopharmacology, Drug Misuse & Novel Psychoactive Substances Research Unit, School of Life and Medical 
Sciences, University of Hertfordshire - stefaniachiappini9@gmail.com 
 
Background: Promethazine is a medicinal product, available on its own or in combination with other ingredients including 
dextromethorphan, paracetamol, and/or expectorants. Anecdotal reports have however indicated that promethazine may 
have a misuse potential, especially in adolescents.  Objective: We aimed at studying how this phenomenon has been 
reported to the European Monitoring Agency (EMA) Adverse Drug Reactions (ADRs) database.  Methods: After a formal 
request to the EMA, the promethazine-specific dataset has been studied performing a descriptive analysis of the 
misuse/abuse/dependence related-ADR reports. The study was approved by the University of Hertfordshire 
(LMS/PGR/UH/03234). Results: The analysis of promethazine data showed increasing levels of misuse/abuse/ 
dependence issues over time (2003-2019). Out of a total number of 1,543 ADRs’ cases, the abuse/misuse/dependence-
related cases reported were 557, with ‘drug abuse’ (300/557: 53.8%) and ‘intentional product misuse’ (117/557: 21.0%). 
being the most represented ADRs. A high number of fatalities were described (310/557: 55.6%), mostly recorded as ‘drug 
toxicity/drug abuse’ cases, with opiates/opioids having been the most commonly reported concomitant drugs used.  
Conclusions: Anecdotal promethazine misuse/abuse reports have been confirmed by EMA data. Promethazine 
misuse/abuse appears to be an alarming issue, being associated with drug-related fatalities. Thus, healthcare professionals 
should be warned about a possible misuse of promethazine and be vigilant, as in some countries medicinal products 
containing promethazine can be purchased over the counter. Since promethazine is often available in association with 
opioids, its abuse may be considered a public health issue, with huge implications for clinical practice. 
 
NPS in Europe  
Christie R.  
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Lisbon, Portugal – 
Rachel.christie@emcdda.europa.eu 
In Europe, a three-step legal framework of early warning, risk assessment, and control measures allows the European 
Union (EU) to rapidly detect, assess, and respond to the public health and social threats caused by new psychoactive 
substances. The EMCDDA is responsible for the first two steps in this system, namely, operating the EU Early Warning 
System (EWS) on New Psychoactive Substances (NPS) in close cooperation with Europol, and conducting risk 
assessments. The European Commission is responsible for proposing control measures. The EU EWS is composed of a 
multiagency and multidisciplinary network, which includes the EMCDDA, 30 national early warning systems, Europol 
and its law enforcement networks, the European Medicines Agency (EMA), the European Commission, and other 
partners. Underpinning each of the national early warning systems (NEWS), and, in turn, the EU EWS, is the exchange 
of information on the chemical identification of new psychoactive substances from forensic and toxicology laboratories.  
This approach allows the collection and rapid reporting of event-based information on the appearance of, and, harms 
caused by, NPS at national level to the EMCDDA. These data are complemented by biannual reports, which include 
aggregated data on seizures by law enforcement and from poisonings. There have been some encouraging developments 
in the NPS market in Europe that have been particularly visible from around 2015 onwards. These include a decrease in 
the number of new substances identified for the first time each year and an overall decrease in seizures, especially driven 
by a drop in seizures of synthetic cannabinoids and cathinones — the two largest groups of new substances monitored by 
the EMCDDA. In part, these changes appear to be related to a disruption in the ‘legal high' trade, which for a period saw 
NPS sold openly on the high street in many countries in Europe. More generally, broader policy responses designed to 
restrict the availability of new psychoactive substances are also likely to have had an effect. However, since 2015 a greater 
proportion of substances associated with problematic use — particularly opioids and benzodiazepines — have appeared 
on the market bringing a new set of problems; while the market in synthetic cannabinoids, once the epitome of the ‘legal 
highs’ phenomenon, has also evolved to pose a threat to health security. During this time, the NPS market has also 
developed stronger links with the markets in established controlled drugs. 
 
Unsupervised supplement intake: an underestimated phenomenon in online fitness settings 
De Luca I.*, Negri A., Townshend H., Giorgetti V., Cicconcelli D., Bersani F.S., Imperatori C., Corazza O. 
* Department of Clinical and Pharmaceutical Sciences, University of Hertfordshire, Hatfield, United Kingdom – 
ideluca348@gmail.com 
 
Background: Supplements use is widely spread among online fitness settings. Particularly, a wide range of vitamins, 
minerals, amino acids or other “ergogenic aids”, which can have both short-term and long-term side effects, are promoted 
and sold with misleading information on the support of weight-loss, muscle gain and performance enhancement. Our 
study focused on the popularity of such compounds in online communities, investigating the main sources of information, 
health risks awareness and possible side effects, through the thematic analysis of internet fora. Methods: A thematic 
qualitative analysis was conducted on 4 popular fitness fora, which were chosen according to (i) relevance of the research 
objective, (ii) activity of the forum and (iii) number of posts (at least 7 per week). Five of the most popular sport 
supplements (creatine, multivitamins, whey protein, nitric oxide, branched-chain amino acids) were used as keywords for 
the analysis. Thematic analysis was performed following five themes: motivations, availability of information, side 
effects, perceived risks of health, contamination issues.  Results: The analysis of fitness fora revealed discussions on a 
considerable number of perceived side effects, health and psychological risks associated with supplement intake, such as 
acne and water retention, weight gain, kidney damage, addiction, etc. Among the sources of information, 21% of fora 
users referred to obtain information from websites and social media, while the 17% relied on fitness influencers’advices. 
Main motivations of intake were muscle gain (23%) and increased energy (10%). Conclusions: Websites and social media 
are among the main sources of supplements’ promotion, with “fitspiration” trends in social media playing a relevant role. 
Additional investigations on supplements intake on online fitness settings are required to further elucidate the extent of 
harm, especially for young people, as well as to support the development of more targeted preventive strategies. 
 
Use of novel psychoactive substances (NPS) of natural origin: an international survey 
Deligianni E.*, Lione L., Kontogiorgis C., Papazisis G., Lazari D. 
* School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece - elena.deligiani@gmail.com 
 
Background: NPS recreational uses are mostly derived and modified from constituents of natural origin. Here we 
investigated the motivation of natural NPS use, perception of potential associated health risks, and demographic factors 
associated with natural NPS use. Methods: The Bristol Online Survey was in English and advertised on the drug forum 
Bluelight and social media Facebook pages and via University email between 1 July and 17 November 2018 (812 
responses). This pharmacoepidemiologic study was evaluated using the SPSS software (IBM SPSS Statistics version 
24;MacOS Sierra 10.12.3). Results: The main motivation (67%) for natural NPS use was curiosity to ‘’experience 
something new and different’’ with a low perception of health risk (85%). The preferred natural NPS was magic 
mushrooms (psilocybin, 95%) often in combination with cannabis (63%). Gender, living area, educational background, 
smoking frequency and employment significantly affected (P<0.001) natural NPS use. Male respondents, residents of 
suburban and rural areas, smokers and respondents with low educational level represented the majority of natural NPS 
users as well as the employed, the unable to work and retired groups. Similarly, sexual orientation significantly affected 
(p<0.05) natural NPS use. Conclusions: Users’ low perception of natural NPS safety profile and the fact that natural NPS 
use correlates with a lower level of education, indicates a need for enhanced statutory targeted prevention interventions 
in schools. Many users (67%) reported natural NPS make them be happier and more optimistic about life emphasising 
the need to study the potential application of these substances in appropriate clinical settings for therapeutic purposes in 
mental health. 
 
Herbal based psychoactive substances in Nigeria: a case for more research in Africa 
Ebuenyi I.D.*, Dumbili E.W., Ugoeze K.C. 
* Assisting Living & Learning (ALL) Institute, Department of Psychology, Maynooth University, Maynooth, Ireland – 
Ikenna.ebuenyi@mu.ie 
 
Background: Studies indicate that although the use of novel psychoactive substances (NPS) is on the increase in Africa, 
there is little data or research in the area. Also, contemporary studies on NPS often preclude studies in Africa. This may 
not be unrelated to the ‘non-classical packaging’ of NPS in homemade and herbal mixtures. The morbidity and mortality 
associated with such psychoactive substances have been subject of many clinical reports and studies.  This study aims to 
explore and highlight the non-classical presentation of NPS in Nigeria and the implications for young people in Nigeria. 
Methods: The data were collected from two exploratory studies. First, an online interview method was used to obtain 
information from 10 young adults (20-35 years) in Southern Nigeria. Additionally, 23 young adults (23-29 years) were 
interviewed on a face-to-face basis in Eastern Nigeria. The data were analysed thematically. Results: The participants 
gave detailed lists of NPS used among young people in contemporary Nigeria. Consuming drug cocktails and 
‘concoctions’ was common among the participants and their friends. Some used what they called Codeine Diet (i.e., 
Codeine-based cough syrup mixed with Malt or Coca-Cola drinks), while others took Gutter Water (a cocktail of 
cannabis, Codeine, Tramadol, vodka, and juice or water). The use of Monkey Tail (a mixture of local gin, cannabis leaves, 
stems, roots, and seeds), petrol mixed with glue and La Casera (carbonated soft drink) combined with Tom-Tom (a 
popular menthol-flavoured candy) was also revealed. Pleasure, better highs, perceived prolonged intoxication, and the 
use of one drug to douse the effects of another substance motivated the use of some of these substances. Conclusions: In 
resource-poor settings, it may be easy to ignore NPS if emphasis is placed on its classical definition. Few studies have 
focused on the chemical assay of these drug cocktails in our setting. Although a few case reports have highlighted the 
clinical sequelae of ingestion of these drug cocktails, there is dearth of research on the short- and long-term consequences 
in Nigeria. It is pivotal that governments, research, and funding organisations commit resources an in-depth systematic 
exploration of the impact of homemade psychoactive substances in low resource settings. 
 
How to detect the use of a new illicit substance by combining different strategy 
Esseiva P. 
School of Criminal Justice, University of Lausanne, Switzerland – pierre.esseiva@unil.ch 
  
Detecting the appearance or use of a new psychoactive substance is not always easy. There are several sources of data 
which are of various nature either linked to a physical environment (analysis of police seizures, analysis of waste water, 
analysis of used syringes...) or to a digital environment (analysis of the darknet, analysis of the forum...). There are also 
many actors (law enforcement, border units, medical emergencies) who have essential data to identify a new phenomenon. 
In this presentation, we will discuss the deployment of different strategies as well as a proposal for the articulation of 
these different sources of information in order to detect NPS or follow the evolution of a specific problem. 
 
Adulteration of Drugs with Toxic Cutting Agents: An Emerging Global Public Health Threat 
Fiorentin T.R.*, Browne T.  
* Center for Forensic Science Research & Education, PA, United States of America - tais.fiorentin@cfsre.org 
 
The last decade has witnessed an outbreak of public health problems resulting from toxic adulterants being added to illicit 
drugs. Some of these adulterants (phenacetin, aminopyrine) are pharmaceuticals that were added to aspirin, but banned 
in the 1960s due to problems such as kidney failure, bladder cancer, and reduction of both red and white blood cells. 
Another adulterant, levamisole, is a de-worming agent for cattle that depletes white blood cells in humans leading to 
depressed immune systems and various infections. These new adulterants include, but are not limited to: banned 
pharmaceuticals, veterinary products, analgesic pain relievers, sedatives, antihistamines, opioid pain medications, muscle 
relaxants, antiarrhythmics, and impurities from the heroin manufacturing process. These compounds have been associated 
with severe health effects, including: decreased production of red and white blood cells due to bone marrow damage, 
multifocal inflammatory leukoencephalopathy, hemolytic uremic syndrome, renal failure, multiple malignancies, life-
threatening cardiac arrhythmias, overdose, and death. This presentation will address the appearance of these toxic 
adulterants in different regions of the world and the unique threats they pose to public health.  
 
Functional and histological changes in rat urinary bladder following short- and long-term Ketamine exposure  
Gant A. *, Benham C., Fergus S., Lione L. 
* University of Hertfordshire, Hatfield, United Kingdom - a.gant2@herts.ac.uk 
 
Background: Due partly to their dissociative properties, ketamine and related new psychoactive substances (NPS) are 
widely used as recreational drugs. This has led to the discovery of a link between the chronic use of ketamine and 
methoxetamine and the development of cystitis, which is typically associated with an array of lower urinary tract 
symptoms indicative of an overactive bladder. Interestingly, however, in vitro organ bath experiments demonstrate that 
acute exposure to ketamine causes relaxation in human bladder. Ketamine has been shown to dose dependently inhibit 
Ca2+ influx through L-type calcium channels in various tissues and species, and so this may contribute to the relaxant 
effects observed following acute exposure. Here, the effects of short term (20 minutes) and longer term (72 hours) 
ketamine exposure on carbachol-induced rat urinary bladder contractility are assessed in an in vitro organ bath assay. The 
mechanisms behind the functional changes observed were also investigated by looking at the effects of ketamine 
following blockade of L-type calcium channels; and through immunohistological assessment of L-type calcium channels. 
Methods: Rat bladder was dissected into longitudinal strips and suspended in organ baths containing 15mL Krebs-
Heneselit solution, supplied with 95% O2 5% CO2, and maintained at 37°C. Strips were contracted with increasing 
concentrations of carbachol and then incubated with ketamine (up to 3mM) for 20 minutes within the organ bath, or 72 
hours in an incubator, before carrying out another carbachol dose response. For histological assessment, rat bladder was 
dissected in half longitudinally and cultured at 37°C with 3mM ketamine for 72 hours, with the other half of the bladder 
acting as a time matched control. Bladders were then fixed in 10% formalin for 24 hours, dehydrated through graded 
alcohols and cleared with xylene, embedded in paraffin wax, sectioned at 5uM thickness and stained for 
immunohistochemical visualisation of L-type calcium channels. Results: Acute exposure to ketamine (≥300µM up to 
3mM) decreased the contractile response of bladder strips to carbachol — a response that is predominantly L-type calcium 
channel dependent. In contrast, longer term 3mM ketamine exposure significantly increased contractility of bladder, 
compared to control tissues. The longer-term effects of organ culture and ketamine on L-type calcium channels will be 
presented. Conclusions: This is the first study to demonstrate in vitro rat bladder overactivity following ketamine 
exposure. Further results will provide insight into the mechanisms behind the functional and histological bladder changes 
induced by ketamine. 
 
NPS in the time of COVID-19  
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Laboratory diagnostics of acute poisoning with new synthetic cathinones (MDPHP, α-PBP) in the Russian Federation 
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Background: In 2018-2020, cases of acute poisoning were recorded in the Russian Federation associated with the use of 
MDPHP(3,4-methylenedioxy-α-pyrrolidinohexanophenone,1-(benzo[d][1,3]dioxol-5-yl)-2-(pyrrolidin-1-yl)hexan-1-
one)) and α-PBP(α-pyrrolidinobutiophenone; 1-phenyl-2-(pyrrolidin-1-yl)butan-1-one), which are homologues of the 
narcotic drugs of 3,4-methylenedioxypyrovalerone (MDPV) and α-pyrrolidinovalerophenone (α-PVP), respectively. The 
aim of the investigation was to study the metabolic pathways of MDPHP and α-PBP in the laboratory diagnosis of acute 
poisoning. Methods: Seven urine samples were collected from patients with acute poisoning with synthetic cathinones in 
different regions of Russia. MDPHP and α-PBP and its metabolites were detected and identified by gas chromatography-
mass spectrometry and high-resolution liquid chromatography - tandem mass spectrometry (LC - HRMS/MS). Results: 
The major pathways of biotransformation for α-PBP and MDPHP were similar to those other synthetic cathinones.  It 
was found that α-PBP and MDPHP undergo extensive metabolism with the formation of a large number of products of 
the 1st and 2nd phase of biotransformation. Metabolites resulting from demethylenation and subsequent methylation 
(MDPHP), reduction of carbonyl group (α-PBP) and oxidation to form a lactam combined with ring-opening (α-PBP and 
MDPHP) were found to be the most useful target analytes for the confirmation of ingestion. The majority of the 
hydroxylated metabolites of α-PBP and MDPHP were found to be glucuronidated. Conclusions: The main pathways of 
metabolism of 3.4-MDPHP and α-PBP were studied. The obtained data can be used to detect and identify new synthetic 
cathinones in the biomaterial of patients with acute poisoning. 
 
Identification, detection and monitoring: What’s next? 
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The UK’s First Home Office-Licensed and Pharmacist-Led Community Drug Checking Service  
Guirguis A.*, Gittins R., Schifano F. 
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Background: Drug-related deaths related to illicit use are soaring with no sign of abating. Emerging psychoactive 
substances with unpredictable adverse effects are still emerging and are posing serious public health risks. On-site “drug 
checking” services in the UK have predominantly operated at festivals without a licence by the Home Office. AIMS: The 
aim of this study was to pilot the UK’s first pharmacist-led, Home Office-licensed community drug checking service to 
enable pharmaceutical analysis and tailored advice in real time. Methods: A bespoke protocol incorporating legally, 
professionally and ethically binding documents was implemented. A free, anonymous, confidential service was designed 
for anyone over 18 who provided informed consent and who agreed to supply a non-returnable drug sample. Samples 
were checked on-site at an established substance misuse service (SMS) using a portable laboratory device to determine 
the likely drug and adulterant content. In parallel, participants completed a questionnaire about their substance use and 
the drug sample(s) being tested. A pharmacist-led multidisciplinary approach was adopted to discuss the pharmaceutical 
analysis findings and communication of the results to the participant, based on which a tailored harm reduction 
intervention was delivered. Results: The pilot operated for four days over four weeks. Eleven people visited and 
relinquished a total of thirteen samples. Half of the participants had previously overdosed and were known to the SMS. 
Seventy percent were male, all were White British 30% were employed and two people disclosed visiting from another 
nearby town. Samples included what was thought to be heroin, synthetic cannabinoids, stimulants, benzodiazepines and 
LSD and none required activation of the ‘alerts cascade’. Most people drank alcohol regularly with concomitant use of 
traditional illicit drugs and prescribed medication (including opioids, anxiolytics and antidepressants) with sedating 
profiles was common. Subjects of different ages and patterns of drug use accessed the service. Given some of the ethical 
decisions and interpretation of the results, specialist clinician involvement was deemed essential. Conclusions: This pilot 
demonstrated the proof-of-concept that a pharmacist-led Home Office-licensed drug checking service can be successfully 
implemented in a community SMS.  
 
NPS prevalence in on Sexual Assault, DUID, and Post-mortem Toxicology Cases in Orange County, CA, USA  
Ha H.H.  
Orange County Crime Laboratory, United States of America - hhh@occl.ocgov.com  
 
Background: Over the past few years, there has been an increase in detection of various novel psychoactive substances 
(NPS) in toxicology cases. To avoid regulations, new substances are introduced to the street daily by simple structural 
modification of known drugs. The Orange County Crime Lab (OCCL) in California is recording a higher count of NPS 
each year with an emphasis on benzodiazepines and mitragynine. Methods: Blood and urine samples submitted to the 
laboratory received screening by Immunalysis Direct enzyme-linked immunosorbent assay kits for amphetamine, 
methamphetamine, THC, and barbiturates. Starting in August of 2018, additional screening by liquid chromatography 
quadrupole time of flight (LC-QTOF) was also performed to analyse for prescription, illicit and over-the-counter drugs. 
Included in this specific broader screen are designer benzodiazepines, novel opioids, bath salts and synthetic 
hallucinogens. Since the LC-QTOF screen has been brought on-line, new synthetic compounds were added when they 
were identified by the Seized Drug section to expand the screen. Positive screened samples received confirmation by 
either gas chromatography mass spectrometry (GCMS) or liquid chromatography tandem mass spectrometry (LCMSMS) 
instrumentation. Results: From 2017 to 2019, 33,753 ante-mortem and post-mortem cases were received and analysed 
for designer drugs. An increase of appearances of various designer benzodiazepines, clonazolam, etizolam, and 
flubromazolam are seen, with flubromazolam having 17 positive samples in 2018 to 57 samples in 2019. Analogues of 
fentanyl; such as acetylfentanyl, β-hydroxy fentanyl and valeryl fentanyl, also increased; with two cases of valeryl 
fentanyl in 2018 and 11 cases in 2019. Mitragynine prevalence also increased more than 80% from 2018 to 2019. Designer 
benzodiazepines are seen in both DUID and post-mortem cases; fentanyl analogues are more prevalence in DUID cases, 
while mitragynine is more common in post-mortem cases. Conclusions: Detecting NPS is important to toxicology 
laboratories to get a true view of what drugs are being abused. The addition of exact mass instrumentation and the 
collaboration with a Seized Drug section aid in determining in what is currently being used in the community. Within 
three years, OCCL went from detecting very few of these drugs to increasing more than 80% for most of the NPS they 
detect. This increase not only had to do with utilizing new instrumentation, but also working more closely with the Seized 
Drug Section. The most common NPS class seen in Orange County, California are designer benzodiazepines, with 
flualprazolam being the most common in the first half of 2020.  
 
Novel designer drug 25I-NBOMe affects neurotransmission and induces neurotoxicity in the rat frontal cortex 
Herian M.*, Wojtas A., Skawski M., Sobocińska M., Madej K. 
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Background: Hallucinogens, a class of novel psychoactive substances, potently alter mood and perception but do not 
produce addiction and dependence. NBOMes are N-benzylmethoxy derivatives of the 2C family hallucinogens that mimic 
LSD effect. 25I-NBOMe (4-iodo-2,5-dimethoxy-N-(2- methoxybenzyl)phenethylamine) exhibits high binding affinity 
for 5-HT2A/2C serotonin receptors. Many case studies confirm serious toxicity and fatalities after 25I-NBOMe intake in 
humans. However, the knowledge of NBOMes effect on the central nervous system is very limited. Therefore, the aim of 
our study was to investigate the impact of 25I-NBOMe on brain neurotransmission and possible induction of 
neurotoxicity. Methods: We examined the effect of 25I-NBOMe single doses on extracellular levels of dopamine (DA), 
serotonin (5-HT) and glutamate in the rat frontal cortex using microdialysis in freely moving animals.Neurotoxic 
properties of 25I-NBOMe were determined by measurement of tissue content of DA and 5-HT, their metabolites 
(DOPAC, HVA and 5-HIAA, respectively), and nuclear DNA damage assessed with the Comet Assay. Furthermore, 25I-
NBOMe presence was analyzed with electrospray ion trap mass spectrometry in the rat plasma and the frontal cortex. 
Statistical analysis was done using Student's t-test or repeated measures ANOVA and comparisons between groups were 
calculated with Tukey post hoc test. Results: Acute administration of 25I-NBOMe increased release of DA, 5-HT and 
glutamate in non-linear manner. It increased 5-HT and 5-HIAA cortical content but did not affect DA, DOPAC and HVA 
tissue levels. The oxidative damage was observed by DNA double and single-strand breaks occurrence. 25I-NBOMe was 
detectable in the blood plasma and rat frontal cortex 15 min after injection. The concentration of the compound was higher 
in the plasma than in the frontal cortex and was dose-dependent. The observed inverted U-shaped dose-response effect 
on DA and 5-HT and U-shaped effect on glutamate levels seem to result from activation, apart from 5-HT2A, 5-HT2C 
receptors by 25I-NBOMe. It is suggested that higher doses of 25I-NBOMe activate 5-HT2C receptor subtype causing 
release of GABA. The inhibitory impact of GABA on pyramidal cells modulates glutamate release that indirectly causes 
changes in DA and 5-HT levels. Observed DNA double and single-strand breaks indicate generation of oxidative stress 
by 25I-NBOMe. However, the lack of tissue monoamine deficits does not point to long-lasting neuronal damage. 
Conclusions: Mass spectrometry data show that 25INBOMe easily crosses the blood-brain barrier which results in its 
immediate effect on neurotransmission. 
 
Emerging Drug Trends in the United States 
Heuett W.J. *, Wong L.L., Herdman C.A., Pressley D.P., Boos T.L. 
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Background: New psychoactive substances (NPS) among the synthetic opioids, synthetic cannabinoids, synthetic 
cathinones, designer benzodiazepines, and other drug classes continue to pose threats to the public health and safety in 
the United States and countries around the world. Over 950 NPS were identified in the past decade, which are being 
monitored domestically in the United States. Methods: We will present the current NPS trends of several major drug 
classes in the United States along with forecasts based on data from the Drug Enforcement Administration’s (DEA) 
National Forensic Laboratory Information System (NFLIS). NFLIS-Drug provides accurate, chemically and/or otherwise 
verified data which is used to identify emerging drugs as well as diversion, trafficking, and abuse patterns geographically 
and over time in support of federal, state, and international drug policy initiatives. We will also consider data from 
multiple other sources, including, but not limited to, the United Nations Office on Drugs and Crime (UNODC) Early 
Warning Advisory on NPS (EWA), the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
European Union Early Warning System on NPS (EWS), and Health Canada Drug Analysis Service (DAS), as they are 
key to early identification of emergent drug patterns in the U.S. Finally, we will highlight the timelines of some select 
substances that have emerged in the U.S. illicit drug market. Results: The impact on the rate of new NPS emerging in the 
U.S. illicit drug market is evaluated following multiple temporary control actions on NPS and a temporary control on 
fentanyl-related substances (FRS) as a class. The number of FRS reports to NFLIS-Drug have noticeably decreased. 
Reports of new synthetic cannabinoids and benzodiazepines have increased in recent years. Select substances highlighted 
will include some FRS, isotonitazine, MDMB-4en-PINACA, and flualprazolam. Conclusions: Early identification of NPS 
emerging on the illicit market requires close collaboration, efficient communication, and the new modality of early 
warning systems to mine, analyse and model data for signals and trends. Challenges remain in this rapidly changing 
landscape, but there have been successes and lessons learned. 
 
In vitro activity-profiling of Cumyl-PEGACLONE variants at the CB1 receptor: fluorination versus isomer 
exploration 
Janssens L.*, Cannaert A., Connolly M.J., Liu H., Stove C.P. 
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Background: Two relatively recent synthetic cannabinoid receptor agonists (SCRAs), Cumyl-PEGACLONE and 5F-
Cumyl-PEGACLONE, were not controlled by the national legislation upon their first detection in Germany in 2016 and 
2017, respectively. Although the highly potent Cumyl-PEGACLONE was initially considered as a relatively safe SCRA, 
in contrast to 5F-Cumyl-PEGACLONE, both compounds have already been linked to several fatalities according to the 
database of UNODC. (5F)-Cumyl-PEGACLONE is now scheduled in most countries, albeit with differing regulatory 
statuses regarding the compounds’ isomers; in Singapore the n-propylphenyl isomers are listed as scheduled compounds 
as well, while this is not the case for the ethylbenzyl isomers. Methods: In this study, the CB1 receptor activation potential 
of (5F)-Cumyl-PEGACLONE, together with two newly synthesized structural isomers (Cumyl-PEGACLONE 
ethylbenzyl isomer and n-propylphenyl isomer), was assessed using two different in vitro receptor-proximal bio-assays, 
monitoring the recruitment of either β-arrestin2 or a modified G protein (mini-Gαi) to the activated CB1 receptor. Results: 
Both in terms of potency and relative efficacy, Cumyl-PEGACLONE and 5F-Cumyl-PEGACLONE were found to exert 
strong CB1 activation, with sub-nanomolar EC50 values, and efficacy values exceeding those of the reference agonist 
JWH-018 >3 fold (β-arrestin2 assay) or almost 2-fold (mini-Gαi assay). Importantly, a postulated difference in the activity 
of 5F-Cumyl-PEGACLONE and the non-fluorinated analogue could not be observed here, as both compounds were found 
to be equally active at the CB1 receptor in these in vitro bioassays. The ethylbenzyl and n-propylphenyl isomers showed 
strongly reduced CB1 activity (EC50 values >100 nM; efficacy <40% relative to JWH-018), which is hypothesized to 
originate from steric hindrance in the ligand binding pocket. None of the evaluated compounds showed significant biased 
agonism towards one of both signaling pathways. Conclusions: the functional assays applied here allowed us to 
demonstrate that 5-fluorination of Cumyl-PEGACLONE is not necessarily linked to an intrinsically higher CB1 activation 
potential, and that the ethylbenzyl and n-propylphenyl isomers yield a strongly reduced CB1 activation, with similar 
activity profiles for both isomers.  
 
Synthetic Cannabinoids in hair – Prevalence in driver’s license regranting in Germany, March – September 2020 
Kutzler J. *, Polettini A., Bleicher S., Sauer C., Schultis W., Neukamm M. A., Auwärter V. 
* SYNLAB MVZ Weiden GmbH, Germany - johannes.kutzler@synlab.com 
 
Background: The use of Synthetic Cannabinoids (SC) has increased during the last decade. Additionally, the structural 
variety of this class expands continuously in order to circumvent generic laws like the German New Psychoactive 
Substances Act (NpSG). When sanctioned for driving under the influence of drugs (DUID) the driver’s license may be 
suspended. In order to regain the withdrawn license, drug abstinence must be proven by negative hair and/or urine samples 
covering an observation period of at least 6 until up to 12 consecutive months, depending on the offense’s severity. 
Methods: In this study, 2995 hair samples from 2693 individuals were analysed for “traditional” drugs of abuse as well 
as SC (qualitatively) during the period of March to September 2020. In this study only requests for the aforementioned 
abstinence control program with at least two successive samplings were considered. All sample details were anonymized 
before SC testing in order to prevent identification. Hair samples were decontaminated, extracted overnight and analysed 
by LC-MS/MS. THC was derivatized prior to GC-MS/MS in negative-ion chemical ionization (NCI) mode. Additionally, 
all specimens positive for SC were analysed with LC-ESI-qTOF-MS in order to search for new SC. In this presentation 
only qualitative results are shown. External contamination could not completely be excluded. Therefore, SC positive 
samples are not regarded as consumption of SCs but contact with the substance. Results: Only 0.4 % of the analysed hair 
samples were requested to be tested for SCs, none of them were positive. During the designated time frame, 577 people 
finished the abstinence control program successfully. However, being negative for all “traditional” drugs, 3.3 % of them 
were still positive for SCs and a quarter had a known history of THC consumption. 44 % of the SC-positive samples 
contained only one SC, in one sample 13 different SCs were found. In the hair samples positive for SC, 5F-MDMB-PICA 
was detected in half of the cases. In addition, seven SCs not covered by the qualitative LC-MS/MS method were found 
by LC-ESI-qTOF-MS and confirmed by semi-quantitative LC-MS/MS. Conclusion: Hair samples from the majority of 
persons reobtaining their driving permit were negative for all “traditional” drugs of abuse during the observation period. 
Nevertheless, 3.3 % were still positive for SCs which are rarely requested for analysis. Our results show that screening 
for SCs (at least of the second hair sample) is recommended in all cases, not only in those where individuals have a known 
history of cannabis consumption. 
 
A comprehensive analytical process from the identification of an NPS threat to systematic screening  
Laquerre J.*, Garneau B., Desharnais B., Côté C., , Taillon M-P., Martin P-Y, Daigneault G., Mireault P., Lajeunesse 
A. 
* Laboratoire de sciences judiciaires et de médecine légale, Department of Toxicology, Montréal, Québec, Canada – 
julie.laquerre@msp.gouv.qc.ca 
 
Background: Despite reports of stabilization in the NPS global situation the phenomenon is still in constant evolution. 
This work aims to tackle NPS screening requirements with a complete NPS process including an early warning system 
(EWS) and a dynamic LC-MS/MS detection method allowing rapid addition/removal of compounds with a minimal and 
efficient validation. Methods: The LC-MS/MS method at the centre of this process relies on a high throughput protein 
precipitation extraction also used for 144 other drugs. A volume of 100 µL of blood/urine is precipitated with 400 µL of 
a 7:3 (v:v) acetonitrile:acetone mixture. The supernatant is diluted with a solution of 1.5% formic acid and injected on an 
Agilent 1200/1260 HPLC coupled to a Sciex 5500 QTrap operated in positive electrospray ionization mode with multiple 
reaction monitoring (MRM). Validation was achieved according to AAFS Standards Board guidelines using 88 extracted 
samples and included evaluation of interferences, carryover, limit of detection, sample extract stability, extraction 
recovery and process efficiency.  New trends were identified by an EWS monitoring detection events inside and outside 
the laboratory. Results: Validation criteria were met for all 57 analytes. Limits of detection (LOD) ranged from 0.01 
ng/mL to 20 ng/mL, and sample extract stability from less than 24h to six days. There was no significant carryover, except 
for cis-3-methyl norfentanyl and flualprazolam, no interferences from 144 other common compounds as well as in 
between NPS screened for. All pair of isomers except isobutyryl norfentanyl and butyryl norfentanyl were resolved by a 
combination of chromatographic separation and careful choice of MRM transitions. Complete integration of the method 
to the existing workflow allowed systematic screening without performing a supplementary extraction and use more 
sample volume. Of the 5 079 cases screened for NPS, 175 (3.4%) tested positive, most of them were drug-impaired 
driving (140 cases, 80%), with only 30 post-mortem cases (17%) and 5 sexual assault cases (3%). New synthetic 
benzodiazepines were detected in 165 cases (94%), novel synthetic opioids in 8 cases (5%), and both categories in 2 cases 
(1%). The implementation of this method yielded a four-fold increase in the positivity rate of NPS. Conclusions: This 
ISO 17025 accredited process has the ability to keep pace with emerging trends as it is integrated to the already 
implemented workflow and thus allow systematic screening of every case. The LC-MS/MS screening method at its centre 
is sensitive, specific and use a widely available instrument. This workflow clearly demonstrated its usefulness in our 
setting, yielding a four-fold increase in NPS detection prevalence but its fundamental concepts can be adapted to any 
analytical workflow using a nonspecific extraction process.  
 
The abuse of analgesic opioids: a clinical case study  
Levari E. *, Stefani M., Franceschini A., Corazza O. 
* Azienda Provinciale per i Servizi Sanitari (APSS), Trento, Italy- ermelinda.levari@apss.tn.it 
 
Background: The abuse of analgesic opioids is a diffuse problem in the United States and in many other countries, 
including Italy, where cases of overdose and death are increasing. The aim of this presentation is to describe a clinical 
case study of a 39-year-old man. Methods: He was diagnosed with neoplastic lesion on the knee about 20 years ago and 
consequently prescribed oxycodone to reduce the pain. He abused the substance, while he was also suffering from 
paranoid schizophrenia and became dependent. He approached our Addiction Service, where he was prescribed 
methadone as a replacement therapy. Contact was made with his general practioner and his previous psychiatrist in order 
to better understand the case. Results: After constant clinical monitoring, the patient managed to recover well. 
Conclusions: We believe that sharing knowledge and working jointly with other professionals are essential to reduce the 
risk of abuse of analgesic opioids and improve the care of patients.  
 
Fentanyl Related Compounds and Designer Benzodiazepines Analyzed by the DEA Laboratory System  
Lockhart E.D.  
U.S. Drug Enforcement Administration - emily.d.lockhart@usdoj.gov  
 
Background: New psychoactive substances (NPS) have continually evolved since appearing in the United States in 2009.  
The timely dissemination of information outlining the NPS currently in the market provides useful information to the law 
enforcement and health communities.  This presentation will illustrate NPS identifications and trends tracked by the Drug 
Enforcement Administration (DEA) Emerging Trends Program. Methods: Data was collected for this analysis through a 
query of archived seizure and analysis information.  The information targeted in this query included the date and location 
of the seizure and substances identified during the chemical analysis performed by the eight DEA chemistry laboratories.  
These seizure details and analytical results are used to compile drug intelligence, detect the appearance of new drugs of 
abuse, and monitor drug trends. Results: The most prevalent NPS identified in the United States fall within the categories 
of synthetic cannabinoids, cathinones, and opioids.  There were 17 substances reported for the first time in CY2019.  
Other chemical classes identified during CY2019 include benzodiazepines, benzofurans, piperazines, and several other 
classes.  Mid-year 2020 data was not available at the time of abstract submission. Conclusions: Due to the ever-changing 
nature of NPS, the criminal justice system is confronted with a unique set of challenges.  Understanding the current trends 
and monitoring the emergence of NPS within the United States enables the health, forensic, enforcement, and legislative 
communities to be better prepared to fight the NPS epidemic.   
 
NPS Discovery: A Program for Early Detection of Emerging Trends in Novel Drugs in the United States 
Logan B.*, Krotulski AJ 
Center for Forensic Science Research and Education (CFSRE), United States of America - barry.logan@frfoundation.org 
 
Background: Early warning systems (EWS) have been demonstrated to be especially effective in accelerating the sharing 
of information about newly emergent substances, which is critical for developing new analytical methods, for monitoring 
their spread and proliferation, for identifying outbreaks of adverse events in vulnerable populations and for prioritizing 
resources for control or scheduling actions. We describe the development and deployment of NPS Discovery in the United 
States with a mission to create a national alert and intelligence infrastructure for information sharing about new drugs, 
their use, and trends linked to public health and public safety. Methods: NPS Discovery was founded in 2018 with a goal 
of coordinating and disseminating activities of the non-profit CFSRE. These activities include new substance 
identifications, metabolomics studies, analytical method development, outbreak investigations, and sharing of 
information. The model has evolved into five primary domains: Intelligence, Surveillance, Monitoring, Response, and 
Forecasting. Dissemination of vital NPS information is shared at each point in this process and report include new drug 
monographs, public health alerts, and quarterly trend reports. Results: Through NPS Discovery, the CFSRE reported 
initial US appearance of twenty novel substances in 2019 and 2020, including six new opioids. Since 2018, 78 novel 
substances have been identified and reported, including stimulants, opioids, opioid precursors, benzodiazepines, 
hallucinogens, and synthetic cannabinoids. Since 2018, eight quarterly trend reports have been released for synthetic 
cannabinoids, six for opioids, and most recently two for benzodiazepines and stimulants/hallucinogens. In addition, public 
health alerts were issued concerning isotonitazene, brorphine, flualprazolam, eutylone, and 4F-MDMB-BINACA, as well 
as an outbreak involving synthetic cannabinoid/fentanyl combinations. During this period, CFSRE scientists also issued 
20 peer reviewed publications describing analytical methods, metabolomics, adverse events, NPS related fatalities, and 
drug trends. These work products were ultimately distributed to an electronic mailing list of governmental, analytical, 
clinical, law enforcement, regulatory and harm reduction stakeholders. Conclusions: NPS Discovery has developed a 
comprehensive surveillance program offering the opportunity for international integration into a global monitoring system 
for NPS drug emergence and trends. This model provides opportunities for early detection, rapid response in scheduling, 
and preparedness by first responders and social services. 
 
Elaboration of generic legislation for phenethylamines in Brazil  
Macedo M.L.S.  
Brazilian Health Regulatory Agency (ANVISA), Brasil - moema.macedo@anvisa.gov.br  
 
Background: The New Psychoactive Substances (NPS) market is very dynamic, requiring new legislative approaches to 
tackle the drug problem. In addition to individual listings, in 2016, Brazil started adopting generic legislation for NPS. In 
2019, continuing this strategy, Brazil adopted the generic legislation for the group of the phenethylamines, class of 
substances with documented psychoactive and stimulant effects that represents significant amount of seizures in Brazil. 
Methods: The generic legislation proposals were developed by an interinstitutional Working Group comprised of Anvisa 
and Ministry of Justice and Public Security. It was based mainly in scientific publications about structure-activity 
relationship, international legislation and materials from United Nations. The exchange of information and experiences 
between different areas (sanitary regulation, forensic, law enforcement and drug police) was fundamental. Results: In the 
generic system, drug control measures foreseen under the individual listing system are extended to a defined group of 
substances, controlling large groups of molecules, without the need to list them individually. This includes substances 
that have not yet been reported, potentially preventing their emergence. It is especially efficient for NPS, since small 
structural changes to already controlled molecules are common in order to circumvent the control measures imposed on 
the original molecules. For the phenethylamine class, the Group proposed two main structures: 1-phenylethan-2-amine 
and 1-phenylpropan-2-amine. Any substances falling within the structural classes described have been banned, with the 
exception of approved medicines. Conclusions: The NPS market continue to shift and diversify at alarming speed, posing 
a significant risk to public health and a challenge to drug policy. The adoption of generic legislation represents an 
evolution in the control system and an important strategy in the fight against the appearance and misuse of NPS. In Brazil, 
the integrated, joint and comprehensive work made possible by the interinstitutional Working Group has been shown to 
be extremely positive in that it allows combating the drug problem on several fronts.   
 
The pharmacometabolomic approach in the investigation of pharmacological effects of physiologically active 
substances using Danio rerio model 
Markin P.A. *, Moskaleva N.E., Tarasov V.V., Tagliaro F., Appolonova S.A. 
* Laboratory of Pharmacokinetics and Metabolomic Analysis, Institute of Translational Medicine and Biotechnology, I. 
M. Sechenov First Moscow State Medical University, Moscow, Russia - markinpavel96@gmail.com 
 
Background: Currently, there is an emerging amount of the so-called novel psychoactive substances, which are the newly 
synthesized drugs that mimic mind-altering drugs of abuse. Regarding this fact, the need for high-throughput models of 
drug screening is rising, and one of the promising models is zebrafish (Danio rerio). Zebrafish is useful for the studies of 
drug effects due to a large amount of physiological and genetic similarities to humans, high reproducibility, and relatively 
low maintenance cost. The main goal of our study was to identify the possibility of using Danio rerio for high-throughput 
screening of potential drugs of abuse to identify the psychoactive properties of drugs based on a targeted metabolomics 
approach. In this study, the pharmacometabolomic assessment was made to investigate the neurotransmitters profiles of 
zebrafish induced by diazepam, a drug of benzodiazepines family, and 5F-APINAC, a novel synthetic cannabinoid. 
Methods: Twenty zebrafish eggs were placed in each well of 6-well plates and were exposed to a wide range of 
concentrations of diazepam (0.8 – 160 ug/L), and 5F-APINAC (0.001 – 10 uM) and each repeat of the experiment had a 
control group. Zebrafish were exposed to the chemicals for a different amount of time – from 2nd to 6th day post 
fertilization (“chronic” exposure) and for 2.5 hours for diazepam or 4 hours for 5F-APINAC at the 6th day post 
fertilization (“acute” exposure). 36 metabolites related to neurotransmitters metabolism were measured using UPLC-
MS/MS approach. Results: Acute exposures. Alterations were found in serotonin, kynurenine pathways, 
dopaminergic/adrenergic system metabolites, and other metabolites related to neurotransmitters metabolism, such as 
aspartic acid metabolism, glutamic acid metabolism, GABA innervation system, acetylcholine system. Statistical 
differences were found in the concentrations of metabolites related to neurotransmitters, such as biopterin and citrulline 
after both diazepam and 5F-APINAC exposures. Chronic exposures. Serotonin, kynurenine pathways, 
dopaminergic/adrenergic system metabolites, and other metabolites related to neurotransmitters metabolism, such as 
aspartic acid metabolism, glutamic acid metabolism, GABA innervation system, acetylcholine system were altered. 
Statistical differences were found in the concentrations of metabolites related to neurotransmitters, such as biopterin and 
citrulline after both diazepam and 5F-APINAC exposures. Conclusions: In this comparative study, zebrafish have shown 
to have the potential to be used as a high-throughput screening model for the investigation of the effects of potentially 
psychoactive drugs. 
 
Club drugs and induced psychopathology 
Martinotti G. 
University “G. d’Annunzio” of Chieti-Pescara, Department of Neuroscience, Imaging, and Clinical Sciences, Chieti, 
Italy; University of Hertfordshire, Herts, United Kingdom - giovanni.martinotti@gmail.com 
 
Background: The knowledge of health professionals on the psychopathological manifestations associated with substance 
intake is still scarce and fragmentary. Induced psychotic experiences are frequent, especially with some specific clusters 
of substances, like stimulants and psychedelics. Despite this, a deep knowledge of their clinical and psychopathological 
manifestations is lacking, as well as the differential diagnosis with primary psychotic experiences. Methods: a review of 
the most relevant studies about this issue will be reported. Some original data about the use of NPS in the island of Ibiza 
will be presented and discussed. Results: The lysergic psychoma is a construct that may be pivotal in the understanding 
of phenomena induced by substances in general, not only by lysergic hallucinogens. This term has its roots in the 
definition made by Hellpach and, most of all, in Bonhoeffer’s hexogen model, in which an external noxa may determine 
and directly influence the development of a full psychosis. Trying to explain in details what happens when an exogenous 
lysergic psychoma is emerging, we need to characterize it as a clear egodystonic experience, in which the subject 
perceives the presence of a “foreign body” in his own mind. The thinking Ego can feel and observe it as an uncommon 
experience, out of control, enriched by hallucinations (mainly visual and kinesthetic), delusional perceptions, and, in 
some cases, structured but confined delusional thoughts. The Ego is still aware and in charge of its role, and usually tries 
to stem and contain the overflowing psychoma. However, taking into account its repetitive nature, the high dosages and 
the long-lasting pharmacokinetic properties of novel compounds, a new scenario may be hypothesized. If unusual 
thoughts or deviant perceptions become permanent, the capacity to deflate them is reduced to be more and more 
inadequate. The thinking Ego may not be able to counteract the psychoma anymore, and the latter can invade the 
functioning part of one’s mind, becoming fully pervasive. This could be the beginning of a psychotic experience, an 
“epidemic” diffusion inside the brain. Conclusions: The onset of psychiatric symptoms after the use of potent and highly 
rewarding drugs appears to be the norm, especially on the long term. These episodes, sometimes with clear psychotic 
features, are often reversible; however, when the use is frequent, persistent, and at high dosages, the onset of full and 
long-lasting disorders is commonly observed. The model of hexogen psychosis may help to understand what happens 
during and after the intake of these substances. More clinical studies are needed in order to clarify these aspects and the 
importance of the hexogen model, not only in the perspective of toxic psychosis. 
 
The Rise of Flualprazolam in DUID, Sexual Assaults and Postmortem Toxicology Cases in Orange County, CA, USA 
Mata D.C.  
Orange County Crime Lab - dmata@occl.ocgov.com 
 
Background: Flualprazolam has over taken etizolam as the most common novel psychoactive benzodiazepine in Orange 
County, CA.  The number of flualprazolam cases has quickly increased with only seven cases in 2018 (starting in August), 
then 123 in 2019 and 119 in the first five months of 2020. Due to this increase, the Orange County Crime Lab decided to 
add flualprazolam to a benzodiazepine by LCMSMS quantitative method in order to report concentrations for ante-
mortem and postmortem toxicology. The objective of this presentation will be to present flualprazolam concentrations 
for driving under the influence of drug, drug facilitated sexual assaults and postmortem cases in blood and tissue samples 
when available. Methods: Initially, 50 µL of Alprazolam-d5 (1000 ng/mL) was added to 0.25 mL of blood, urine or 
vitreous humor or 0.25 g of liver homogenate, brain homogenate, or gastric content homogenate. The protein was 
precipitated out of the sample with 0.75 mL of cold acetonitrile. The supernatant was then aspirated and dispensed on 
DPX-WAX tips three times, holding it on the tips for approximately 15 seconds with each aspiration. The final elutant 
was diluted with mobile phase and injected onto a Waters Acquity UPLC coupled to a Waters TQ-S triple quadrupole 
mass spectrometer utilizing positive electrospray ionization in multiple reaction monitoring mode. A Waters BEH C18 
1.7 µm column (2.1 x 100 mm) held at 40°C with a gradient mobile phase of 0.1% formic acid in water and 0.1% formic 
acid in acetonitrile at 0.4 mL/min was used for chromatographic separation. A quadratic curve, weight 1/x2, was used for 
the range of 4 – 256 ng/mL with two control samples at 100 and 10 ng/mL. Results: For ante-mortem cases the average 
flualprazolam concentration is 22.56 ng/mL (median = 15.26 ng/mL) with a range of 4.03 – 133.3 ng/mL. For that same 
time frame, postmortem cases had an average concentration of 17.58 ng/mL (median = 9.59 ng/mL) and a range of 4.82 
– 48.03 ng/mL. The flualprazolam tissue distribution for the postmortem cases varied greatly, but flualprazolam was 
detected in all matrices. THC and its metabolites along with other benzodiazepines (prescribed and non-USA prescribed) 
were the most common drugs found in conjunction with flualprazolam. Conclusions: With the data collected from this 
method a more thorough comparison to DRE findings, driving patterns and autopsy findings can be examined. 
Unfortunately, as with most other drugs, there are very few flualprazolam only cases. These few cases will be discussed 
at the end of the presentation.  
 
A timeline of the co-detection of 4-Fluoroamphetamine and 25C-NBOMe in Australia  
Matheson A.*, Griffiths A., Collins-Brown L. 
* Queensland Health Forensic and Scientific Services, Queensland, Australia - abbey.matheson@health.qld.edu.au 
 
Not available   
 
A Sentinel Population: The public health benefits of monitoring enhanced body builders 
McVeigh J. *, Salinas M., Ralphs R. 
* Substance Use and Associated Behaviours, Department of Sociology, Manchester Metropolitan University, Manchester, 
United Kingdom - j.mcveigh@mmu.ac.uk 
 
Background: There is heightened recognition of the public health implications of anabolic androgenic steroids (AAS) for 
the use of image and performance enhancement; with increasing evidence of their long-term negative health impacts, the 
hazards associated with their administration (often via injection), and the variability and unpredictability of their contents. 
In order to optimise the effects of these drugs, together with strict dietary and training regimes, AAS users typically 
supplement their use with an expansive and continually evolving range of ancillary drugs. The discovery and subsequent 
adoption of these drugs by the broader AAS user population is largely dependent upon a minority of social influencers 
within the bodybuilding community. Pioneering enhanced bodybuilders who self-experiment with a diverse range of 
image and performance enhancing drugs (IPEDs) and ancillary drugs have been the forerunners in the development of an 
underground user-led literature, online discussion forums, and were early adopters of internet-facilitated drug markets. 
Yet the impact of their self-experimentations extends well beyond the enhanced bodybuilding community, particularly in 
their use of ancillary drugs. Most significantly has been their role in the diffusion of various enhancement and 
psychoactive drugs to the wider population. Methods: Using the theoretical framework of the 'diffusion of innovation' we 
consider the role that pioneering enhanced bodybuilders have played in the diffusion of various enhancement and 
psychoactive drugs to the wider population through a focus on three substances –dinitrophenol (DNP), melanotan II and 
gamma-hydroxybtyrate (GHB). Results: With an increasing range of drugs used by bodybuilders, coupled with an 
expansion in the use of online forums and online platforms to purchase pharmacological and new psychoactive drugs, we 
anticipate this trend of diffusion amongst the wider population will continue to flourish. Conclusions: Therefore, we 
highlight the need for policy makers to monitor emergent trends, not only in the general AAS population but particularly 
amongst enhanced bodybuilders. 
 
‘Keeping Control’: The ethics of prosecuting substance abuse offenses in the COVID pandemic  
Menendez M.J. 
Department of Justice, Organized Crime Drug Enforcement Task Forces, United States of America - 
Menendezusa@outlook.com 
 
Not available 
 
Metabolism study of N-methyl 2-amino Indane (NM2AI) and determination of metabolites in biological samples by 
LC-HRMS 
Mestria S. *, Odoardi S., Federici S., Biosa G., Valentini V., Marti M., Strano Rossi S.  
* Università Cattolica del Sacro Cuore F. Policlinico Gemelli IRCCS, Rome, Italy - serenamestria@gmail.com 
 
Background: Since the widespread diffusion of NPS, forensic laboratories are required to identify new drugs and their 
metabolites for which information or reference standards are lacking. Their identification in biological samples is very 
challenging, since the concentrations are extremely low, and they may be present mainly or solely as metabolites. As their 
metabolic pathways are often unknown, metabolism studies are necessary. Aminoindanes represent a relatively new 
generation of NPS. In recent years, these drugs have been increasingly reported to the UNODC Early Warning Advisory. 
None of them is currently under international control. Very little is known about their acute behavioural, toxic effects and 
metabolism. Methods: We performed a study on N‐methyl‐2‐aminoindane (NM2AI) metabolism in silico and in vivo, to 
identify the main metabolites for biological samples screening. In silico metabolism prediction of NM2AI was performed 
using MetaSite software. The metabolites presence was verified in vivo (mice’s blood, urine, and hair) after NM2AI 
administration. Samples were analysed by liquid chromatography–high-resolution mass spectrometry (LC-HRMS) with 
a benchtop Orbitrap Exactive. We subsequently evaluated the agreement between software prediction and experimental 
results in biological samples. Results: LC-HRMS analysis identified seven main metabolites in the urine. They were 
identified, by their accurate masses and fragmentation patterns, as: 2-aminoindane (2AI), two hydroxy-2AI and four 
hydroxy-NM2AI; one of the hydroxy-NM2AI and one of the hydroxy-2AI also underwent conjugation. The study 
demonstrated the good concordance between in silico and in vivo results. The most probable metabolic products predicted 
by the software (2AI, two hydroxylated metabolites, and hydroxy-2AI) were found in authentic mouse urine; NM2AI and 
2AI were also detected by LC-HRMS in the hair and blood samples. Based on these findings, we developed an LC-HRMS 
method for the screening of NM2AI and metabolites in urine, blood and hair samples. This can be of primary effectiveness 
to uncover the abuse of NM2AI and related possible intoxications. Conclusions: NM2AI was extensively metabolized; 
seven metabolites were identified in urine, marking the importance of metabolite identification for documenting NM2AI 
intake. In any case, the parent compound was always present at high concentrations. The present study marks one of the 
first developments of analytical methods for clinical, forensic and epidemiological investigations of NM2AI and 
metabolites in different bodily specimens. The identification of new or neglected compounds can be useful for the 
improvement of the Early Warning Systems, allowing the identification of NPS, whose use and toxicity, otherwise, would 
be underestimated. 
    
Monitoring Synthetic Cannabinoid Trends in the United States 
Mohr A.L.A.*, Krotulski A.J., Logan B.K. 
*Center for Forensic Science Research and Education, United States of America - mandi.mohr@frfoundation.org 
 
Background: Since 2008, the synthetic cannabinoid illicit drug market has continued to change and evolve with one or 
more major new drugs being identified in the United States on a quarterly basis. These synthetic cannabinoids are 
subsequently identified in emergency room patients, impaired drivers, death investigations, and high-profile intoxications. 
Understanding the scale and scope of these events requires comprehensive analytical testing, which is frequently lacking 
due to the rate with which new compounds appear. From a laboratory standpoint, the challenges of remaining current 
with synthetic cannabinoids stem from the diversity of compounds in the class; the large number of analogues, 
configurations, and isomer; and the delays in availability of analytical standards to confirm presence in biological samples. 
Methods: In order to stay current with changing landscape of synthetic cannabinoids, a novel approach using both 
biological samples and sample extracts that had previously be tested were analysed using a comprehensive non-targeted 
data acquisition method by high resolution liquid chromatography time-of-flight mass spectrometry (LC-QTOF).  The 
library was regularly updated with emerging synthetic cannabinoids and their metabolites as they became available and 
ultimately resulted in a database with 288 synthetic cannabinoid parent compounds, metabolites, and internal standards. 
Acquired data was regularly reprocessed against the updated library to determine retrospectively the date of first 
appearance and spread of new compounds as they appear on the drug market. Results: Over the course of 15 months, 38 
different synthetic cannabinoid related analytes were detected (25 parent compounds and 13 metabolites) which correlated 
to at least 27 unique synthetic cannabinoids. 5F-MDMB-PICA was the most prevalent analyte identified during this 
funded research, followed by 5F-MDMB-PINACA, MMB-FUBINACA, and 4F-MDMB-BINACA. Through the second 
quarter of 2020, 5F-MDMB-PICA continued to be the most frequently detected synthetic cannabinoid. MDMB-4en-
PINACA was identified for the first time in the first quarter of 2020 and 5F-EMB-PICA in the second quarter. 
Conclusions: In the United States, synthetic cannabinoids pose significant challenges for public health and public safety 
agencies. New synthetic analogues that target endogenous cannabinoid receptors continue to appear on recreation drug 
markets, sometimes increasing in potency and toxicity in comparison to previous generations. Using this approach, we 
developed a model that allowed for the timely identification and dissemination of newly identified synthetic cannabinoids. 
Current trends suggest that new synthetic cannabinoids appear on a monthly basis, but typically only one (or two) 
analyte(s) will proliferate and dominate the market for roughly one year in time. Continued vigilance efforts must be 
maintained to stay current with evolving market.    
 
The NIST Fentanyl Classifier 
Moorthy A.S.*, Kearsley A.J., Mallard W.G., Wallace W.E. 
* National Institute of Standards and Technology, Gaithersburg, MD, United States of America - arun.moorthy@nist.gov 
 
Background: Fentanyl is a highly addictive synthetic narcotic originally developed for treating severe pain. The growth 
in the abuse of fentanyl, fuelled in part by “designer” fentanyl analogues, has led to an unprecedented rise in overdose 
deaths. The large and rapidly evolving number of these drugs presents a challenge in chemical identification. This 
presentation will describe the application of mass spectral similarity mapping towards the classification of designer 
fentanyl analogues. Methods: Mass spectral similarity mapping is a natural extension to traditional mass spectral 
similarity searching. In both processes a query mass spectrum of the analyte is searched against a library of reference 
spectra. Whereas a traditional similarity search provides an analyst with a hit list -- a high confidence way of identifying 
an analyte with a replicate spectrum in the library -- similarity mapping provides a map that is informative even for 
analytes that are not in the reference library such as new designer drugs. A mass spectra library that included fentanyl and 
“Type I” fentanyl analogues was collected, where “Type” indicates the number of modification sites by which an analogue 
differs from the standard fentanyl scaffold. Mass spectral similarity maps can be generated using query spectra and the 
fentanyl library. These maps can be scrutinized to classify the query based on the likely site of modification and, in some 
instances, propose a complete structure for the query. An open-source implementation of mass spectral similarity mapping 
applied to fentanyl analogues, referred to as the NIST Fentanyl Classifier, is available at https://github.com/asm3-
nist/FentanylClassifier. Results: The NIST Fentanyl Classifier (NFC) was tested using several example spectra, including 
replicate spectra of fentanyl, replicate spectra of the Type I fentanyl analogues contained in the library, spectra of Type I 
fentanyl analogues not represented in the library, spectra of Type II analogues, and spectra of non-fentanyl compounds. 
As expected, the NFC correctly localized modification sites for fentanyl analogues that differ from fentanyl by 
modification on at most two sites (i.e. Type I and Type II fentanyl analogues). In cases where the query was a Type II 
fentanyl analogue with “composing cognates” contained in the library, the NFC was able to accurately identify the query 
short of positional isomers. Conclusions: The NIST Fentanyl Classifier is a new tool that applies mass spectral similarity 
mapping to the analysis of fentanyl and fentanyl analogues. It has demonstrated applicability and limitations, both of 
which will be described in this presentation. 
 
NPSfinder: a systematic tool to identify novel psychoactive substances (NPS) by crawling the pro drug/’psychonaut’ 
websites  
Napoletano F*, Schifano F., Corkery J.M., Guirguis A., Arillotta D., Zangani C., Vento A.  
* Psychopharmacology, Drug Misuse, and Novel Psychoactive Substances Research Unit, School of Life and Medical 
Sciences, University of Hertfordshire, Hatfield, United Kingdom - flavia.napoletano@nhs.net  
 
Background: The online market for new psychoactive substances is developing much faster than academic research. In 
addition to the traditional websites, cryptomarkets have also recently been developed. These are anonymous sites that 
operate on the so-called "darkweb" and are accessible only through specially configured browsers. Vulnerable subjects, 
including children/adolescents and patients with psychiatric illnesses, may be exposed to web pages that provide 
opportunities to purchase drugs and/or drug information. “NPSfinder” is a “crawling/navigating” software that was 
designed by the Rome (I)-based Drug Surveillance Unit and the informatics’ Damicom team. Methods: NPSfinder allows 
to map on a 24/7 basis the large variety of psychoactive molecules mentioned within the range of major online psychoanut 
web sites/fora. NPSfinder is a tool able to extrapolate a range of information regarding NPS, including: chemical and 
street names; chemical formula and IUPAC nomenclature; three-dimensional image; and, when available, anecdotally 
reported clinical/psychoactive effects. These data are automatically stored into an online database, which is Located 
within firewall protected, highly secure, and consistently performing servers. NPSfinder’s goal is to map the entire 
number of existing psychoactive molecules and smartdrugs on the internet. Results: After about 18 months of operation, 
the number of substances identified by the web crawler activities was 5922; of these molecules, 4192 different molecules 
were included in the database and 1730 (29.2%) of the remaining molecules were false positives/duplicates. Hence, one 
could provisionally reckon that the online/psychonaut web fora NPS scenario might include in the region of 4000 different 
molecules. The researchers assigned each molecule to its drug class, with the following classes having been identified: 
aminoindanes, synthetic cannabinoids, cathinone derivatives, psychedelic phenethylamines, synthetic opioids, novel 
stimulants, tryptamine derivatives, phencyclidine-like dissociatives, piperazines, GABA-A/B receptor agonists, a range 
of prescribed medications, psychoactive plants/herbs, and a large series of image-and performance-enhancing drugs 
(IPEDs). The most popular NPS mentioned in the psychonauts’ fora included: phenethylamines (30.1%); synthetic 
cannabimimetics (29.8%); synthetic opioids (10.2%); synthetic cathinones (4.1%), designer benzodiazepines and other 
GABAergic drugs (4.1%); and prescribed drugs (3.8%). Conclusions: NPSfinder is a useful tool to facilitate the process 
of early recognition, it allows to follow a phenomenon that otherwise would be difficult to monitor constantly, due to the 
increasingly dissemination of new substances online and the instability of information sources. The early identification 
of NPS has crucial medico-legal implications and will also bring significant benefits to the daily clinical practice of 
physicians working in both emergency departments and general psychiatry. 
   
Carfentanil advertised on the darknet: potential scam or alarming public health threat? 
Negri A.*, Townshend H., McSweeney T., Angelopoulou O., Banayoti H., Prilutskaya M., Bowden-Jones O., Corazza O. 
* School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom, Postgraduate School of 
Pharmacology and Clinical Toxicology, University of Milan, Milan, Italy - attilio.negri@ospedaleniguarda.it 
 
Background: In an age of global insecurity, highly potent synthetic drugs have increasingly been used to harm others. 
Their online advertisement and sale are facilitated by surface web, darknet markets and social media fuelling various 
types of new criminal activities and their growth in sophistication. This study presents a systematic analysis of the darknet 
sale of one of the most potent synthetic opioids: Carfentanil. With an equianalgesic potency of 10.000 times a unit of 
morphine, its toxicity is comparable to traditional nerve agents, and it has been previously used as a chemical weapon, 
causing human fatalities. Methods: Digital trace data was collected retrospectively from all the darknet marketplaces, 
which have been active in the past five years. Data on vendors offering Carfentanil on Agartha, Empire and Yakuza 
marketplaces were analysed with regard to items sold and sellers’ features as these were the only active markets at the 
time of search. Searches were carried out in the English language only. Results: 63 different Cartfentanil vendors 
operating on 19 darknet marketplaces were identified. Contacts and payments were facilitated with end-to-end encryption 
messaging mobile applications and content-expiring messages. Although it is known that Agartha is a scam market, and 
no operative sellers were found on Yakuza, several sellers promoting Carfentanil sales were active in Empire marketplace, 
with a number of transaction ranging from 4 to 1223. Conclusions: The availability of highly potent drugs such as 
Carfentanil on the darknet requires the development of innovative scientific methods and tools able to monitor and predict 
such new threats, while informing policymaking and protecting the health and the security of citizens.  
 
Mapping NPS policy in the EU: legal frameworks, healthcare provision and outcomes  
Neicun J.  
Department of International Health, Care and Public Health Research Institute (CAPHRI), Maastricht University, 
Maastricht, The Netherlands - jessica.neicun@maastrichtuniversity.nl 
 
Background: The rise in NPS trade and use as well as the lack of information concerning their risk to drug users’ health 
pose serious challenges to European public health authorities. The aim of this contribution is to present a general 
assessment of NPS-related policies implemented by ten European countries through the lens of legal epidemiology. 
Methods: A mapping review of drug-related legal instruments and policy documents was performed. It was followed by 
comparative analysis aimed to identify main features of NPS-related policies implemented across Europe (Belgium, 
Czech Republic, England, France, Germany, Ireland, Poland, Portugal, The Netherlands, Scotland). The conceptual 
framework used for the analysis encompasses law philosophical principles, institutional arrangements and the specificity 
of policies. Law’s intended and incidental effects on health was assessed based on countries drug-related health outcomes. 
Results: The countries under study can be placed in a wide spectrum according to the general principles that define their 
drug policy. Those who have implemented specific legal responses to NPS are based on different regulatory models, from 
blanket bans to generic and individual classification of substances. Besides, the implementation of harm reduction 
interventions (awareness campaigns, drug checking services and monitoring systems) are among the public health 
responses provided by some countries regardless the legal status of NPS. However, prevalence of NPS use seems to be 
more linked to general availability of psychoactive substances (including illicit drugs) rather than to law enforcement 
measures, while punitive measures seem to have a negative impact on NPS-related intoxications and deaths. Conclusions: 
There is still limited development towards harmonisation of national drug policies within Europe, particularly with regard 
to NPS. Although harm reduction interventions seem to have a positive impact on preventing intoxications and managing 
drug poisonings, drug tests available at harm reduction, clinical and forensic services are not able to effectively identify 
emerging molecules and their pharmacological effects. To tackle the challenge presented by NPS, a wider collaboration 
among law enforcement and healthcare professionals across Europe, as well as specialised training for healthcare 
professionals in identifying adverse effects of NPS, may represent a good way to improve healthcare provision and drug 
users ‘health. 
 
The detection of synthetic cannabinoid receptor agonists in infused papers from prisons in a constantly evolving illicit 
market  
Norman C.*, McKirdy B., Walker G., Dugard P., Nic Daéid N., McKenzie C. 
Leverhulme Research Centre for Forensic Science, University of Dundee, United Kingdom - cznorman@dundee.ac.uk
  
Background: In Scotland, synthetic cannabinoid receptor agonists (SCRAs) are almost exclusively used in prisons, with 
little use in the wider community. The majority of SCRAs are infused into paper and card and enter the prison via the 
mail system, where they are vaped. Scottish prisons can therefore act as an early warning system for the emergence of 
new SCRA compounds and modes of use. Qualitative and quantitative laboratory-based methods were developed for the 
detection of SCRAs on infused paper and an evaluation of field-deployed ion trap mobility spectrometer (ITMS) 
instruments used in prisons to screen SCRAs in incoming mail was carried out. The utility of near real-time screening of 
samples seized from Scottish prisons for monitoring and intelligence purposes was explored. Methods: Methods for the 
qualitative and quantitative analysis of SCRA infused papers were developed using gas chromatography-mass 
spectrometry (GC-MS) with qualitative confirmation by ultra-high-pressure liquid chromatography (UPLC-PDA-QToF-
MS) and applied to non-judicial seized paper samples from Scottish prisons. 392 non-judicial paper samples seized from 
four Scottish prisons between June 2018 and December 2019 were examined. Additional data on the SCRAs detected in 
samples seized between September 2019 and August 2020 showing the continuing evolution of the SCRA market in 
prisons will also be presented. Results: From June 2018 to December 2019, 392 seized paper samples from four Scottish 
prisons suspected of being infused with controlled substances were analysed and 46% were positive for at least one 
SCRA, concentrations ranging from <0.05-1.17 mg/cm2 paper. After September 2019, the prevalence of MDMB-4en-
PINACA increased and by March 2020 was the most commonly detected SCRA in Scottish prisons. Our evaluation of 
two ITMSTM instruments confirmed that both instruments were effective for the testing of prison samples with up to 
95% agreement with laboratory-based GC-MS analysis. Conclusions: A method for the qualitative and quantitative 
analysis of SCRAs in paper was developed, validated, and successfully applied to a large number of samples seized from 
Scottish prisons. This has provided near real-time information of the emergence of new SCRAs in the prison system, 
reflecting international market trends. The Rapiscan Itemiser® 3E and Itemiser® 4DN ion trap mobility spectrometerTM 
(ITMSTM) systems were found to be effective for the rapid in-field presumptive detection of SCRA infused papers and 
used effectively, will help to reduce the supply of SCRAs in the prisons. Future work will focus on the training of 
operational staff to indicate the emergence of new SCRAs on the market and on the development of methods to predict 
instrument response for compounds yet to emerge.  
    
Functional characterization of hallucinogenic NPS using different 5-HT2AR bioassays  
Pottie E.*, Cannaert A., Stove C.P. 
* Laboratory of Toxicology, Ghent University, Belgium - eline.pottie@ugent.be 
 
Background: Hallucinogenic new psychoactive substances (NPS) continue to comprise a large portion of newly detected 
substances. While being a structurally divergent group, they share their main pharmacological mechanism: the activation 
of the serotonin 2A receptor (5-HT2AR), which is responsible for the typical hallucinogenic effects. Due to the rapid pace 
at which these substances emerge on the drug market, they are -and often remain- poorly characterized in terms of potency 
and efficacy. Furthermore, the structure-activity relationship of these compounds and their mechanisms on a molecular 
level remain to be elucidated further. Methods: For the characterization of compounds, new bioassays monitoring the 
activation of 5-HT2AR by hallucinogenic NPS were developed, to complement the previously reported transient βarr2 
recruitment assay. More specifically, a stable cell system of the latter was generated, for reduced experimental variability. 
Furthermore, also a transient system employing an engineered miniGαq protein, was optimized, which, together with the 
βarr2 assay, enables the assessment of signaling bias for hallucinogenic compounds at this receptor. All bioassays were 
based on a luminescent readout, following functional complementation of a split nanoluciferase (NanoBiT technology). 
Results: During the series of experiments, several endpoints were assessed, of which the results will be presented: First 
of all, the performance of the developed βarr2 stable cell line was compared to that of the previously developed βarr2 
transient bioassay, finding a high comparability of the results. Secondly, a panel of thirty structurally diverse compounds 
was tested in the new stable βarr2 bioassay. This enabled the establishment of a structure-activity relationship between, 
among others, 2C, NBOMe, NBOH and amphetamine-like compounds (DOx). As a third outcome, the simultaneous use 
of the transient bioassays for βarr2 and miniGαq recruitment, gives an estimate of the signaling bias that could be inherent 
to certain compounds. For this purpose, a set of 13 compounds was subjected to the two bioassays, identifying 4 
significantly biased agonists. Conclusions: In conclusion, the reported bioassays and their use for the assessment of 
characteristics of hallucinogenic compounds, provide an estimate on the structure-activity relationships between these 
compounds, their potencies and efficacies and their characteristics on a molecular level. Furthermore, the results obtained 
with the stable βarr2 cell system, show significant correlation with estimated common dose estimates.  
 
Is Kratom (Mitragyna speciosa) a safe medicinal aid? A Netnographic Analysis of Experiences and Comments on 
YouTube™ 
Prevete E.*, Hupli A., Marrinan S., Singh D., D’ Udine B., Bersani G., Kuypers K.P.C., Ramaekers J.G., Corazza O. 
* Department of Neuropsychology and Psychopharmacology, Maastricht University, Maastricht, The Netherlands - 
e.prevete@maastrichtuniversity.nl 
 
Background: Kratom (Mitragyna speciosa) is a plant native to Southeast Asia with history of traditional medicinal use. 
The aim of this study was to investigate its safety and therapeutic benefits as reported on YouTube videos. Methods: Data 
from the most viewed videos were extracted via the machine learning algorithms generated by the YouTube Application 
Programming Interface (API). Results: A total of 500 videos with 19,478,180 views and 134, 863 comments emerged 
from this data scrape. 12 out of the 16 most viewed videos were manually processed and selected for inductive thematic 
analysis. Kratom was described here as an aid to self-treat various health conditions, such as opioid dependence/addiction 
(83.4%), pain (75%), anxiety (67%) and depression (42%), substance use problems (42%) as well as for energy boosting 
(50%), mood elevation (25%) and nootropic effects (25%). Although most of the described experiences were positive 
(58%), side-effects such as dependence and withdrawal (50%), nausea (42%), loss of appetite (25%), sedation (25%), 
loss of motivation (16.7%), headache (16.7%), drowsiness (16.7%), dry mouth and frequent urination (16.7%) were also 
reported and linked in 25% of the cases to chronic ingestions. Conclusions: The current YouTube videos provide 
promising insights about the medicinal potential of Kratom use. Further controlled clinical studies are needed to better 
determine the therapeutic efficacy and long-term perils of Kratom use. 
 
Facing ever-changing trends: prevalence and patterns of New Psychoactive Substances use in the young population 
of Kazakhstan  
Prilutskaya M.  
Semey Medical University, Department of Personalised Medicine and Pediatrics, Kazakhstan - 
mariyapril2407@gmail.com 
 
Background: The strong association between the young age and NPS use has received increased attention in various 
studies. As for 2012, the Kazakhstan cluster-based survey in educating youth revealed that 15.8% of young people have 
used drugs in their lifetime. The national assessment of NPS prevalence among hospital-based drug users demonstrated 
a stable upward trend over the three-year period (2016-2018): from 3.91% to 10.01% of all drug dependence-related 
hospitalizations in the country. Just above a quarter of the subjects were under 25. The aim of this study was, therefore, 
to obtain the initial insights into the socio-demographic determinants, patterns and correlates of NPS use in the young 
population of Kazakhstan. Methods: The cross-sectional study was conducted in 17 major cities across Kazakhstan in 
July 2019. The target population was young people aged 18-34. The quota sampling was based on the proportions within 
the given age group and its gender distribution. The sample size was set at 1500 respondents. Results: The proportion of 
those who used NPS at least on one occasion was 6.3% (5.2; 7.7), which ranged between different regions from 0 to 
12.0% (7.5; 18.0). NPS users prevailed in men, aged 25-29. Up to 3.4% (2.6; 4.4) used NPS in the last 12 month, 2.4% 
(1.7; 3.3) - in the last 30 days. Two thirds of the respondents inhaled synthetic cannabinoids, just above a half consumed 
synthetic cathinones with various routes of administration. Overall, 30% of NPS users bought drugs from dealers, the 
same proportion got NPS through social messengers (e.g. Telegram, VIpole). The youth reporting NPS use were also 1.5, 
1.23 and 7 times more likely to use tobacco, alcohol and illegal drugs, respectively, compared to respondents who did not 
report NPS use. Conclusions: Compared to the other Central Asian countries, the prevalence of NPS use in the 
Kazakhstani young population is considerably higher and corresponds with an upward trend of NPS hospitalizations in 
drug treatments clinics. NPS in the context of polysubstance use pose a serious concern and should be monitored 
especially in the challenging time of pandemic changes. 
 
How to maintain activities during a crisis period 
Rabin O.  
World Anti-Doping Agency, Canada - Olivier.Rabin@wada-ama.org 
  
In this short video, Dr Olivier Rabin, Senior Executive Director for Sciences and International Partnerships at the World 
Anti-Doping Agency (WADA), will briefly describe how WADA reacted to the initial phase of the COVID-19 pandemic 
and quickly adapted its operations to protect the health of its personnel, to maintain its core activities and to provide 
guidance to the international anti-doping community. In particular the essential role played by rapid collection of reliable 
local and international information and objective opinions provided by internal and external experts to ensure solid 
decisions were taken by the Agency to guide our stakeholders and guarantee continuity of international activities in the 
early phase of the crisis. 
 
Profiling NPS in human clinical trials  
Ramaekers J. 
Maastricht University, Netherlands - j.ramaekers@maastrichtuniversity.nl 
 
New Psychoactive Substances (NPS) are non-scheduled drugs ("legal highs") that mimic the effects of traditional drugs 
of abuse. The unprecedented proliferation of NPS on the drug market threatens public health and challenges drug policy. 
Information on their clinical pharmacology and toxicity is in most cases very limited. Given the large number of new 
compounds released on the market each year a timely evaluation of NPS by current standards in ex-vivo and in-vivo 
animal models or expert evaluations is unfeasible. We recently created a machine learning algorithm employing the 
quantification of metabolomics in rats to predict the similarity of new drugs to classical ones of abuse. The model 
successfully predicted the pharmacological profile of a synthetic cannabinoid (JWH-018) as a cannabinoid-like drug and 
synthetic cathinone (mephedrone) as a MDMA-like psychostimulant. As a follow-up, we propose a targeted imaging-
metabolomics approach in humans that provides fast classifications of NPS and their effects on brain function.   A 
predictive model based on machine learning algorithms will use the quantification of neurotransmitters, 
endocannabinoids, steroid hormones and their metabolites in blood, functional connectivity in resting state brain networks 
and neurocognitive function to predict the similarity of a new drug to classical drugs of abuse. As a proof of concept, the 
model will be tested to forecast the impact of NPS on brain function based on their metabolome in blood. Our approach 
will support fast risk classification of NPS and benefit public health. 
 
 
Methadone as a possible cause of two healthy teenagers’ death 
Rapaccini V.*, Metastasio A. 
* University of Tor Vergata, Rome, Italy - rapaccinivalentina@gmail.com 
 
Background: There have been significant changes in adolescent consumption habits over the past fifteen years., especially 
due to the fact that new molecules have been synthesized, new devices created, and a number of products have increased 
in popularity. Methods: We report the case of two 15 and 16-year-old adolescents died during sleep after the assumption 
of a lethal unidentified mixture. The teenagers accidentally purchased methadone instead of codeine in order to prepare 
a Purple Drunk, a dangerous cocktail commonly used by teenagers, made popular by American rappers and social 
networks; it generally combines codeine-based cough syrup, antihistamines such as promethazine and soda. After taking 
the cocktail containing methadone, both boys experienced fatigue, dizziness, drowsiness and widespread nonspecific 
abdominal pain; these symptoms forced them to stop the football match they were playing with friends and to go home. 
After a few hours they died during sleep. Results: At the moment heart failure is considered the most likely cause of death 
but the autopsy did not detect congenital or acquired cardiac abnormalities in both patients. Currently, toxicological tests 
are in progress to clearly identify the specific components of that lethal mixture containing methadone responsible for 
both patients’ death. 
   
PIEDS and psychopathology: the clinical issues  
Simonato P. 
Parco dei Tigli Hospital, Italy - pierluigi.simonato@gmail.com 
 
Background: The presence of Performance and Image Enhancing Drugs (PIEDs) amongst general population and patients 
is arising, as described by the Keep Fit study of the University of Hertfordshire. During our activity in a Dual Diagnosis 
Unit located in the North East of Italy (Clinica Parco dei Tigli, Padova) the use of these supplements and products has 
been largely reported with some serious consequences regarding the psychopathological state and the risk of dependences. 
Methods: We collected some clinical cases where the use of PIEDs, the presence of classic substances (e.g. cocaine) and 
some psychopathological (like Exercise Addiction [EA] and Body Dysmorphic Disorder [BDD]) were assessed and 
treated. Results: In our clinical experience the presence of these compounds is essential for a correct diagnosis. PIEDs 
can mislead the treatment and must be identified by clinician in order to give some advice and correct information about 
PIEDs’ health risks. In particular the relation between PIEDs and some psychopathological issues (EA, BDD), as explored 
in the Keep Fit results, has been confirmed by clinical evidence. Conclusions: The use of PIEDs should be always 
explored both amongst general population and patients, because the health professional must a) provide correct 
information regarding each class of compounds and their side effects b) guide every intervention considering their 
presence and the psychopathological risk related to them. 
 
Treatment Compliance among Incarcerated and Fined Amphetamine-Type-Stimulant (ATS) Users in a Community 
Supervision Programme in Malaysia: A Preliminary Study 
Singh D. *, Saref N., Narayanan S., Griffin O.H., Vicknasingam B. 
* Centre for Drug Research, Universiti Sains Malaysia, Penang, Malaysia - darshan@usm.my 
 
Background: People caught using amphetamine-type-stimulants (ATS) in Malaysia can either be incarcerated and 
subsequently be placed in a community supervision programme or if they can afford the fine, be directly sent for 
community supervision. We sought to determine if treatment compliance in the community supervision varied between 
the two groups. Methods: Eighty-five ATS users (59 previously incarcerated persons and 26 having only been fined) were 
recruited from a community supervision programme for this longitudinal study. The sample was largely male and Malay. 
Respondents were screened for drug use and assessed for six months. Results: We found that 54% of the incarcerated 
participants had dropped out of the supervision programme as compared to 23% of the fined participants. Also, by the 
end of the study period, 63% of the incarcerated participants had tested positive for drug use, relative to 30% of the fined 
participants. Furthermore, incarcerated participants had higher odds of having previously dropped out of a community 
supervision programme (OR: 4.34; 1.44-13.06; p<.006), as compared to their fined counterparts. Conclusions: ATS users 
with a history of incarceration had poorer treatment compliance, relative to their compeers who were not incarcerated and 
placed directly in a community supervision programme. 
 
The Relationship between Amphetamine-Type Stimulant (ATS) Use and Violent Crime in Penang, Malaysia: Findings 
from a Preliminary Study 
Singh D. *, Narayanan S., Krishnan H., Singh B., Vicknasingam B. 
* Centre for Drug Research, Universiti Sains Malaysia, Penang, Malaysia - darshan@usm.my 
 
Background: Although a few studies have described the association between amphetamine-type-stimulant (ATS) use and 
crime, the relationship still remains inadequately investigated. This study examines the link between the length of ATS 
use and violent crime, in a sample of ATS offenders detained in a police custody in Penang, Malaysia. Methods: One 
hundred and forty-nine offenders with current ATS use history were recruited for this cross-sectional study. All the study 
data was collected through face-to-face interviews with a semi-structured questionnaire. Results: The majority were males 
(93%, n=138/149), and the respondent’s mean age in the study was 36.19 years (SD=11.51). Sixty-two percent (n=93/149) 
had six-years ATS use history, and 60% used ATS >4 days per week (n=89/149). The majority used ATS for its 
stimulant/stamina effects, to overcome boredom and stress. Computation of unadjusted odds indicated that long-term 
ATS users had higher odds of physically assaulting their crime victims in the last six-months (OR: 2.34: 1.16-4.72; 
p<.016), used ATS before committing crime (OR: 2.87: 1.45-5.69; p<.002), and committed crime with the use of a 
dangerous weapon (OR: 3.35: 1.59-7.07; p<.001). However, these differences were not evident in multivariate logistic 
regression analysis. Conclusions: Our preliminary findings show that prolong ATS use serves as a risk factor for offending 
behaviours in Malaysia. Thus, targeted treatment interventions are needed in lieu of incarceration, to reform offenders 
with drug use problems. 
 
Kratom (Mitragyna speciosa Korth.) Use among Opioid Users with Amphetamine-Type-Stimulant (ATS) Use History 
in Malaysia  
Singh D.*, Narayanan S., Vicknasingam B., Prozialeck W.C., Smith K.E., Corazza O., Henningfield J.E., Grundmann O. 
* Centre for Drug Research, Universiti Sains Malaysia, Penang, Malaysia - darshan@usm.my 
 
Background: Kratom (Mitragyna speciosa Korth.), an indigenous plant of Southeast Asia, has been traditionally used for 
its medicinal value, and as a cure or substitute for opioids/heroin in the Siamese-Malay states, despite the fact that it is 
not recognized as a legal medicine by the Malaysian National Pharmaceutical Regulatory Agency. Though kratom is 
reported to produce opioid and stimulant like-effects, studies of its use and perceived utility among opioid users who also 
use amphetamine-type-stimulants (ATS) remain limited. We investigated reasons for kratom use among opioid users with 
ATS use problems in Malaysia. Methods: A total of 427 opioid users with ATS use problems were recruited through 
convenience sampling from five Community Care and Rehabilitation Centres for this cross-sectional study. Survey 
responses were collected with a semi-structured questionnaire. Results: Of the total sample, 332 participants were kratom 
users and 95 were not. Among regular kratom users, the mean duration of kratom use was 6.9 years (SD=1.69). Most 
used kratom decoctions to suppress heroin withdrawal symptoms (77%). More than half used kratom as an ATS or heroin 
substitute (59%), while 58% used kratom to reduce heroin use alone. Multivariate analysis results show that long-term 
opioid users with ATS use problems had higher odds of using kratom for prolonged periods (p<.018), and as a substitute 
for ATS (p<.023). Short-term users were more likely to use kratom to suppress heroin withdrawal symptoms (p<.006). 
Conclusions: Opioid users with ATS use problems, commonly used kratom for long-term periods to reduce dependence 
from both types of these addictive illicit substances. There are currently no pharmacotherapies clinically indicated or 
approved for ATS use disorder treatment. Findings merit further exploration as polydrug users with ATS problems in this 
study reported ATS substitution with kratom. 
 
Treatment Barriers Associated with Amphetamine-Type-Stimulant (ATS) Use in Malaysia 
Singh D.*, Narayanan S., Shanmugam T., Vicknasingam B. 
* Centre for Drug Research, Universiti Sains Malaysia, Penang, Malaysia - darshan@usm.my 
 
Background: Several published studies have already shown reluctance among amphetamine-type-stimulant (ATS) users 
to seek treatment. This study investigated the problem in Malaysia. Methods: 386 ATS users were recruited from five 
compulsory drug detention centres (CDDCs) for this cross-sectional study. The data were elicited through interviews and 
a semi-structured questionnaire. Results: The majority of ATS users were males (83%, n=321/386) and only 17% 
(n=65/386) were females. The commonly reported ATS treatment barriers include self-reliance in treating ATS use, fears 
of discrimination by the community, peer influence, lack of confidence in the community supervision program in aiding 
recovery, long waiting time for treatment, lack of family support, shame of staying in a treatment centre, difficulties in 
registering for treatment, and lack of desire to give up ATS use. Female ATS users had higher odds of reporting fears of 
community discrimination (OR: 1.80, 1.03-3.12, p<.037), peer influence (OR: 1.89, 1.10-3.25, p<.020), and long waiting 
time for treatment (OR: 2.74, 1.58-4.72, p<.000), as compared to male ATS users. Conclusions: Several important barriers 
inhibit ATS users from seeking treatment in Malaysia. 
 
Effects of External Influences on Synthetic Cannabinoid Trends in New Zealand, 2014 to 2020   
Stansfield C.R.*, Somerville R.F., Hassan V.R., Kolbe E., Partington H.K., Walsh K.A.J., Johnson C.S.  
* The Institute of Environment Science and Research (ESR), New Zealand - chrissy.stansfield@esr.cri.nz  
 
Background: Changes in the type of synthetic cannabinoid used in the "synthetic cannabis" plant material may be 
influenced by factors, such as the availability of synthetic cannabinoids, enforcement activities, media attention and 
legislative changes. The Institute of Environmental Science and Research Ltd (ESR) commonly encounters synthetic 
cannabinoids in New Zealand during routine drug testing of domestic and border seizures by enforcement agencies. In 
2017, a nationwide survey of “synthetic cannabis” preparations was carried out in response to significant harm, including 
multiple deaths, attributed to the use of these substances. This synthetic cannabinoid survey has been carried out on three 
separate occasions between 2017 and 2020. Monitoring of border seizures of synthetic cannabinoids has been carried out 
since 2014. A summary of the recent trends in synthetic cannabinoids in New Zealand will be presented, along with some 
explanations as to the changes observed. Methods: Between May 2017 and February 2020, 380 domestic seizures of 
“synthetic cannabis” plant material were submitted to the ESR laboratory for analysis. From October 2014, there were 
313 border seizures of synthetic cannabinoid powders analysed at a screening laboratory operated by ESR analysts. 
Samples were analysed using a combination of Fourier Transform infrared spectroscopy (FTIR), gas chromatography-
mass spectrometry (GC-MS), and/or nuclear magnetic resonance (NMR) techniques. Results: Between October 2014 and 
February 2020, there were a total of 31 different synthetic cannabinoids identified at the border screening laboratory. 
Eleven of these were identified only once during this period, with another 12 being detected less than ten. During the 
three surveys of domestic plant material seizures, a total of 12 different synthetic cannabinoids were detected. The 
synthetic cannabinoids AMB-FUBINACA and 5F-ADB were most prominent in the first two surveys (between May 
2017 and March 2019), accounting for 89% and 77% of detections respectively. In the third survey (between June 2019 
and February 2020), the most popular synthetic cannabinoids were 5F-MDMB-PICA (50% of detections), 4F-MDMB-
BINACA (22% of detections) and 5F-CUMYL-PINACA (14% of detections). Conclusions: Media attention and 
enforcement activities may result in temporary changes to synthetic cannabinoid availability. Similarly, changes to 
legislation in the importing country, where the actual drug use is intended to occur, has been shown to initially influence 
the availability of synthetic cannabinoids. A third influence on synthetic cannabinoid trends is legislative control in the 
source country of synthetic cannabinoid synthesis and distribution.   
 
Detection of Synthetic Opioids, Synthetic Cathinones, and Synthetic Cannabinoids in Wastewater in the U.S. – A 
Promising Community Early Warning System 
Subedi B. 
Department of Chemistry, Murray State University, Murray, KY, United States of America - bsubedi@murraystate.edu. 
 
Background: A few new psychoactive substances (NPS) that mimic the effects of controlled neuropsychiatric and illicit 
drugs have been forensically identified in the U.S. Wastewater-based epidemiology (WBE) can provide a comprehensive 
and more cost and time-effective method of determining the prevalence of NPSs in communities. Monitoring NPS in 
wastewater routinely utilizing state-of-art analytical methods can provide the prevalence of NPSs in community or mass 
gatherings. The routine monitoring of NPSs in wastewater would assist law enforcement for the community drug 
surveillance as well as event planners, risk managers, and emergency medical service personnel to evaluate the audience 
behaviour in mass gatherings. Methods: An analytical method capable of simultaneous determination of forty NPS 
residues (synthetic opioids, synthetic cannabinoids, synthetic cathinones, piperazines, indole, and amphetamine 
derivative) was developed and validated. Raw wastewater collected from four southern communities in Illinois were 
extracted using solid phase extraction and analysed with ultra-high-performance liquid chromatograph tandem with 
quadrupole mass spectrometer. Raw wastewater discharged from a high school basketball game and a college basketball 
game that were played in the same stadium in Kentucky were also analysed for NPSs. Isotopic dilution mass-spectrometric 
method of quantification was employed. Results: Nine NPSs (carfentanil, furanyl fentanyl, methoxyacetyl fentanyl, 
MAB-CHMINACA, methcathinone, 4-methyl pentedrone, 2-methyl-4’-(methylthio)-2-morpholinopropiophenone 
(MMMP), 1-(3-chlorophenyl)piperazine (mCPP), and 5-(2-Aminopropyl)indole (5IT)) were quantified. Methcathinone 
was the most frequently detected NPS (detection frequency, df = 100%) followed closely by the MMMP and mCPP (df 
= 91%). The mass loading of methcathinone, mCPP, and 5-IT, using ammoniacal nitrogen-based population, were up to 
21.1 ± 1.3 mg/d/1000 people, 15.0 ± 0.5 mg/d/1000 people, and 9.75 ± 2.72 mg/d/1000 people, respectively. Two 
synthetic cathinones (methcathinone and 4-methylpentedrone) and three other NPSs (4-ANPP, mCPP, and 4-
methylamphetamine) were also quantified in wastewater indicate the prevalence of NPSs in Kentucky. This is the first 
study to determine the occurrence of NPSs including synthetic opioids, synthetic cannabinoids, synthetic cathinones, and 
piperazines in the U.S. communities and mass gatherings. Conclusions: Several NPSs can be detected and quantified in 
raw wastewater. The routine screening of several NPSs utilizing state-of-art analytical method can be used as an early 
warning system for the community prevalence of NPSs. 
 
Identification of 11 substances known as “smart drugs” in Japan  
Tanaka R.*, Kawamura M., Hakamatsuka T., Ruri Kikura-Hanajiri R. 
National Institute of Health Sciences, Kanagawa, Japan - r-tanaka@nihs.go.jp  
 
Background: In recent years, substances known as “smart drugs”, also known as “nootropics”, have been detected in 
Japan. The smart drugs have been used in the hope of enhancing human brain activity. These substances are easily 
imported and can be used without a prescription. However, the quality, effectiveness, and safety of these products have 
not been confirmed. In this study, 11 substances known as “smart drugs” were isolated and identified from the products 
sold as reagents in Japan. Methods: The 11 white powdery products in small plastic containers were obtained in Japan 
between October 2015 and November 2019. Although these products were sold as reagents on the internet, each container 
was labelled with the name of the substance considered to be a smart drug. The product was extracted with methanol, 
followed by filtration by centrifugal filter. The resultant solution was analysed by LC-ESI-MS and GC-EI-MS. The 
accurate mass spectrum of the target substance was measured by LC-QTOF-MS. Identification of the substances was 
performed by NMR (1H-NMR, 13C-NMR, HMQC, HMBC, H-H COSY). Results: As a result of the LC-ESI-MS and 
GC-EI-MS analyses of the 11 products, 11 substances were detected. Five of these substances were identified as Adrafinil, 
CRL-40,941, Fenozolone, Coluracetam and PRL-8-53 by comparing the data with those of the authentic substances. The 
other six unknown substances were analysed by the LC-QTOF-MS and NMR, and identified as N-Methyl-cyclazodone, 
N-(2-Cyanoethyl)phenylethylamine (PEA-P), 1-Phenyl-2-propylaminopentane (PPAP), p-F-Deprenyl, Unifiram and 
Morphodrol. Each substance corresponded with the name labelled on the container. The analytical data of LC-ESI-MS, 
GC-EI-MS and NMR showed that each of these products consisted of almost a single substance. Of these, PEA-P is 
classified as a group of phenethylamines, and p-F-Deprenyl is an analogue of Deprenyl, developed as a drug for 
Parkinson’s Disease. Coluracetam is a substance developed as a drug for Alzheimer’s Disease. Adrafinil and CRL-40,941 
are analogues of modafinil, a psychostimulant, used for the treatment of narcolepsy. Conclusions: Most of the substances 
detected in this study are analogues of pharmaceuticals. Since these pharmaceuticals have pharmacological effects on 
central nervous system, an excessive intake of these analogues may cause health problems. 
 
Prevalence and social-cognitive determinants of the use of Performance Enhancing Substances by Portuguese Gym-
Goers 
Tavares A.S.*, Serpa S., Rosado A., Horta L., Carolino E., Marôco J., Calmeiro L. 
* H&TRC - Health and Technology Research Center, Lisboa, Portugal - ana.tavares@estesl.ipl.pt 
 
Background: The use of performance-enhancing substances (PES) occurs among gym goers, which is seen as a public 
health concern. The aim of this study is to investigate the extent of PES use and the social-cognitive determinants which 
influence the intention to use these substances among gym goers, according to the Theory of Planned Behaviour. Methods: 
A convenience sample of Portuguese gym goers (n = 453; 61,3% female; 38,7% male) completed an anonymous web-
based survey about beliefs, attitudes, social influences and intentions towards use of PES as well as self-reported PES 
use. A two-step approach to maximum likelihood, structural equation modelling, multigroup analysis and t-test with the 
Welch correction for heteroskedastic variances were performed using IBM SPSS/AMOS 24.0. Results: 11.01% of the 
participants reported PES use. At the structural level, results support attitudes (b = 0.21; p < 0.001), beliefs (b = 0.35, p 
< 0.001) and subjective norms in predicting intentions to PES use in gym goers with subjective norms (b = 0.50; p < 
0.001) being its strongest predictor. Moreover, results showed a significant association self-reported PES use and 
intentions to use (b = 0.66, pp < 0.001). The predictive model was invariant across gender; however, compared to males, 
females believed less in the performance enhancing effects of PES, were less prone to the influence of significant others 
and had weaker intentions to use these substances. Conclusion: Preventive interventions should focus on influencing 
subjective norms, alongside to beliefs and attitudes towards PES use as these variables influence the intention to use PES 
in this particular population. 
 
The Growing Complexity of the Opioid Crisis 
Tettey J. 
United Nations Office on Drugs and Crime, Austria - justice.tettey@unodc.org 
 
The current opioid crisis is a far-reaching drug and public health policy issue affecting several geographical regions. Since 
its appearance, efforts have been made both at the national and international level to develop integrated policy responses 
to address the crisis. Yet, despite some progress, the crisis continues to deepen in complexity with the emergence of a 
new generation of new psychoactive substances (NPS) with opioid effects, including substances belonging to chemical 
structural classes which were not significantly present on illicit drug markets previously. The presentation provides an 
overview of the multi-faceted opioid crisis and highlights major international and domestic policy responses to date. It 
presents selected key developments related to NPS with opioid effects, examines how these developments are influenced 
by existing control measures and outlines possible policy responses. 
 
Acute effects of a moderate dose of a synthetic cannabinoid (JWH-018): implications for psychosis  
Theunissen E.L.* 
* Section Psychopharmacology, Neuropsychology & Psychopharmacology, Faculty of Psychology and Neuroscience, 
Maastricht University, Maastricht, The Netherlands - e.theunissen@maastrichtuniversity.nl 
 
Background: Synthetic cannabinoids are being used for more than 10 years, but placebo-controlled studies into their 
effects are still scarce. SC’s are much more potent than natural cannabis, and as a result many survey’s report more 
psychological problem. In the current study we investigated the subjective drug response to an acute dose of the synthetic 
cannabinoid JWH-018 up until 4 hours after administration. Methods: In this placebo-controlled study, 24 healthy 
participants received a dose of 75µg/kg bodyweight JWH-018. Their subjective intoxication was recorded and reached a 
minimum level before the test day was continued. The acute effects on psychedelic symptoms, dissociative state and 
mood were measured with subjective rating scales (resp. Bowdle visual analogue scales, Clinician Administered 
Dissociative States Scales (CADSS) and Profile of Mood Scales (POMS)). Results: Data were analysed using a GLM 
Univariate ANOVA with Drug (placebo and JWH-018) as a within subject factor. The within factor Time was added in 
case a test was taken more than once on a test day. Subjective high was significantly increased after the JWH-018 
administration and maximum subjective high (average 6.4cm) was reached 30 minutes after administration. After 4 hours 
the subjective score did no longer differ from baseline. The Bowdle scales External and Internal perception, and high and 
drowsiness were significantly increased after JWH-018 intake. JWH-018 significantly increased the CADSS scales 
amnesia, depersonalization, derealisation and total score. Fatigue, Confusion and Arousal scales of the POMS differed 
significantly from placebo and baseline after administration of JWH-018. Conclusions: It is concluded that JWH-018 is 
able to induce psychotomimetic effects in healthy participants with no history of mental illness. 
 
In vitro functional characterization of a panel of non-fentanyl opioid new psychoactive substances  
Vandeputte M.M.*, Cannaert A., Stove C.P.  
* Laboratory of Toxicology, Ghent University, Belgium - marthe.vandeputte@ugent.be  
 
Background: The landscape of new psychoactive substances (NPS) is constantly evolving, with new compounds entering 
the illicit drug market at a continuous pace. Of these, opioid NPS form a particular threat owing to their high potency and 
prevalence. Whereas previously, the use of fentanyl and fentanyl derivatives was the main point of attention, legislations 
have reacted accordingly, which may have been a driving force towards the (ab)use of alternative μ-opioid receptor 
(MOR) agonists. In contrast to fentanyl (analogues), details on these novel non-fentanyl opioid NPS are scarce. However, 
the increasing amount of case reports on (sometimes fatal) intoxications involving these drugs stresses the danger of this 
knowledge gap. Methods: We investigated the biological activity of a panel of 11 ‘alternative’, newly emerging MOR 
agonists (2-methyl-AP-237, AP-237, bromadol, brorphine, butorphanol, isotonitazene, mitragynine, 7-OH-mitragynine, 
MT-45, piperidylthiambutene and tianeptine) using two previously reported, closely related in vitro MOR activation 
assays monitoring either G protein (mini-Gi) or β-arrestin2 (βarr2) recruitment. The assays are based on the functional 
complementation of a split nanoluciferase (NanoLuc Binary Technology®, Promega): activation of MOR, fused to one 
part of the nanoluciferase, leads to recruitment of either βarr2 or mini-Gi, fused to the other part. This results in a 
restoration of the enzymatic activity, producing a measurable bioluminescent signal upon addition of a substrate. This 
set-up also allowed the assessment of biased agonism via previously published equations with hydromorphone as an 
unbiased reference compound. Results: Activity profiles were obtained for all tested compounds, with values for potency 
(EC50) ranging from 1.89 nM (bromadol) to >3 μM (AP-237 and tianeptine). Bromadol, brorphine, isotonitazene, 
piperidylthiambutene and tianeptine had the highest efficacy (Emax) values, exceeding that of the reference compound 
hydromorphone ≥1.3-fold (βarr2 assay) and >2.6-fold (mini-Gi assay). In both assays, butorphanol, mitragynine and 7-
OH-mitragynine were partial agonists compared to hydromorphone, the reference compound. No statistically significant 
bias was found for any of the tested MOR agonists. Conclusions: This study is the first to systematically investigate the 
in vitro biological activity of a diverse panel of emerging non-fentanyl opioid NPS at MOR. Pharmacological profiling 
of such novel substances is crucial to make a realistic estimation of the potential danger their use might bring along. This, 
in turn, may allow to prioritize legislative efforts towards controlling (variants of) these emerging drugs. Given the high 
potencies and efficacies of many compounds in the studied panel, intensive monitoring and proactive control measures 
remain of paramount importance.  
  
First report on brorphine: the next opioid on the deadly new psychoactive substances’ horizon?  
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Background: New psychoactive substances (NPS) continue to appear on the drug market. Until recently, new synthetic 
opioids, which are amongst the most dangerous NPS, primarily encompassed analogues of the potent analgesic fentanyl. 
Lately, also other new synthetic opioids have increasingly started to surface. This is the first report on the identification 
and full chemical characterization of online sourced brorphine, a novel potent synthetic opioid with a piperidine 
benzimidazolone structure. Brorphine was identified in a powder and quantified in two serum samples of a patient seeking 
medical help for detoxification. Methods: Chemical characterization of the powder was performed by liquid 
chromatography high resolution mass spectrometry (LC-HRMS), gas chromatography (GC)-MS, LC diode array 
detection (DAD), Fourier-transform infrared (FT-IR) and NMR spectroscopy analyses. In vitro biological activity of 
brorphine was determined by a cell-based µ-opioid receptor (MOR) activation assay. Patient samples were analyzed with 
a quantitative LC-HRMS method and with the bio-assay. Results: LC-HRMS identified an exact mass of m/z 400.1020 
and 402.1005 for the compound, corresponding to both bromine isotopes. GC-MS, LC-DAD and FT-IR spectra were 
obtained from the powder. 1H- and 13C-NMR-analyses confirmed the structural configuration of brorphine. An EC50 of 
30.9 nM (13.5 ng/mL) and an Emax of 209%, relative to hydromorphone, were derived from the bio-assay, confirming 
the high potency and efficacy of this compound. The potency of brorphine approaches that of the potent analgesic fentanyl 
(EC50 of 18.7 nM). In two serum samples of the patient (taken approximately 60 hours apart), brorphine and a hydroxyl 
metabolite were found using the LC-HRMS method. The obtained brorphine concentrations in the first and second serum 
sample were 69.4 and 7.9 ng/mL, respectively. The presence of opioid activity in the serum was also confirmed via the 
MOR activation assay. Conclusions: The occurrence of brorphine is yet another example of how the illicit drug market is 
continuously evolving in an attempt to escape international legislation. The online availability of this compound, 
combined with its non-scheduled nature in many countries, its unequivocal identification in serum samples from a patient, 
and the demonstration that it acts as a strong MOR agonist: all these aspects should alert toxicology labs, as new cases - 
including fatalities involving brorphine - may emerge. 
 
Spice stories from the slammer - real life experiences of NPS users in prison 
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NPS have posed significant difficulties in UK prisons over the last 5 years. Specifically, synthetic cannabinoids have 
become the most widely used drug in UK prisons, contributing directly to instability, disruption, debt and prison staff and 
prisoners feeling less safe. Part of the challenge is fully understanding the reasons people use 'Spice' and the impact that 
it has on them - only then can we provide the support that will be effective. At HMP & YOI Parc we have embarked on 
an ambitious educational project, capturing real life 'Spice stories' from the residents that reside with us. We hope that 
these perspectives will help us all to better understand the many issues associated with the use of NPS so that we can 
shape our solutions to suit. 
   
 
 
   
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
